2023

Sustainability Report

We’ll Go First
Innovation is at the core of everything we do.
At Glaukos, we push the limits of science andtechnology to solve unmet needs in chronic eyediseases for the benefit of patients worldwide.

INTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

TABLE OF CONTENTS

SOCIALENVIRONMENTAL

APPENDIXOUR REPORTINTRODUCTION
CEO message
2023 sustainability highlights and achievements

3

GLAUKOS
Patients
Our novel platforms

6

SUSTAINABILITY PROGRAM
Sustainability governance and council
Topic prioritization, evaluation, and goal setting

10

GOVERNANCE
Ethics and governance
Responsible procurement practices
Cybersecurity and data privacy

14

PRODUCTS
Product quality and patient safety
Product innovation
Access, affordability, and pricing

24

SOCIAL
Talent attraction, development, engagement, and retention
Diversity and inclusion
Workforce health and safety

38

ENVIRONMENTAL

55

APPENDIX
Goal summary
Expanded metrics-at-a-glance
GRI and SASB content index
Disclaimer

59

3

PRODUCTS

We are proud to present Glaukos’ fifth annual Sustainability Report covering
the 2023 calendar year, January 1, 2023, through December 31, 2023. This
report covers all Glaukos operations and does not address the performanceor operations of our suppliers, contractors, customers, or other third parties
unless otherwise stated.
This report references the Global Reporting Initiative (GRI) and Sustainability
Accounting Standards Board (SASB) frameworks. We did not seek external
assurance for this report.
Glaukos Internal Audit conducted a review of this report primarily focused onreviewing documentation in support of 2023 metrics, goal attainment, andother numerical measures reported. Certain non-numerical disclosures, e.g.,customer stories or policy statements, are also included within the scope ofInternal Audit’s review. Forward looking statements or assumptions are notvalidated by Internal Audit. Our management Disclosure Committee reviews
our annual Sustainability Report prior to publication. The Compensation,
Nominating, and Governance Committee of our Board of Directors provides
oversight of the Sustainability Program.
To provide feedback or for questions on this report, please contact
sustainability@glaukos.com.
GRI 2-2; GRI 2-3

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXA MESSAGE FROM OUR CEO

We are pleased to provide this 2023 report on our
progress to advance key Corporate Sustainability initiatives
that we believe strengthen our organization and contributeto the betterment of the communities we serve, while also
helping to drive shareholder value over time.
Our mission at Glaukos is to truly transform vision bypioneering novel, dropless therapies that can meaningfully
advance the standard of care and improve the lives ofpatients suffering from chronic, sight-threatening diseases.
Innovation is at the core of everything we do, and we areresolute in our commitment to challenge conventional
thinking with new treatment alternatives that are supported
by real science, robust clinical evidence, and an unrelenting focus on patients.
Our constant pursuit of game-changing technologies that
disrupt legacy treatment paradigms is encapsulated in the
Glaukos mantra “We’ll Go First.” It articulates our willingness to take chances, our determination to forge new
ground, and our commitment to continuous improvement
in all that we do. I believe the programs, policies, andachievements detailed in this report offer compellingexamples of our dedication to the “We’ll Go First” ideal
and its fundamental importance to our culture and brand.

and persistence. I would also like to thank the members of
our Sustainability Council, who help our organization
remain focused on key sustainability initiates that align withour business objectives and compile a comprehensive
annual report. In closing, we believe Glaukos is different.
We are change agents. We are pursuing ground-breaking
innovation designed to improve the vision and quality oflife for millions of people suffering with sight-threatening
diseases. Our goals are ambitious, and we believe
tremendous opportunity lies ahead to benefit patients,
investors, and all Glaukos stakeholders worldwide.
Thank you for your interest and support of Glaukos.
Sincerely,

Thomas W. Burns
Chairman and Chief Executive Officer
GRI 2-22

I would like to acknowledge the support and guidance our
Board of Directors provides as we continue to grow andenhance our Corporate Sustainability efforts, as well as theexcellent work of Glaukos employees worldwide who put
our strategies into action with professionalism, enthusiasm,
4

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIX

2023 SUSTAINABILITY HIGHLIGHTS AND ACHIEVEMENTS
FDA approval of iDose® TR, arevolutionary glaucoma therapy
representing 15+ years of intense
research and development from
ideation to commercialization

Established a second product distribution
site, resulting in reduced shipping costs andelimination of 6.4 million air miles

Launched employee
student loan
reimbursement
programThis contributed to reduced emissions
associated with those flights amounting toa total CO2 GHG emission estimatedat 1,286 tons
Launched Glaukos World Café, a DEIrelated learning session focused on
exploring and discussing relevant topics
Launched iDose Your Dosephilanthropic initiative. For every iDose
sold, Glaukos will make available
another iDose at no cost to qualifying
charities
5

Expanded GPS, enrolling nearly
3,000 keratoconus patients andsupporting them on their journey
to corneal cross-linking treatment

Provided approximately $10.5 million in
product donations to underserved
regions around the world$500M ZERO
Invested in R&D since 2018
to advance innovations,representing 30%+ ofrevenues

ISO

Product recalls>16K
Employee learning
activities offered

Certification obtained for
Burlington site, signifying
our commitment toenvironmental management
system standards>6K

Hours of employee
learning anddevelopment

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXGLAUKOSAt Glaukos, our focus is to develop and lead theglobal ophthalmic market with novel therapies
that advance the existing standard of care andenrich the lives and treatment alternatives forpatients worldwide.

KEY FACTS

17 913 $315M

Countries withdirect sales
operations

Employees
worldwide

2023 net sales worldwide

Our global headquarters is located in Aliso Viejo, California, and we have additional locations
San Clemente, California and Burlington, Massachusetts, as well various regional office spaces
internationally. Our manufacturing operations for the iStent® trabecular micro-bypass
products and iDose TR are in San Clemente. We manufacture our proprietary corneal systems
in Burlington, with pharmaceutical therapies primarily manufactured and supplied by third
parties in the United States and Germany.
Our company completed an initial public offering in June of 2015, and our shares trade on
the New York Stock Exchange under the ticker symbol “GKOS”.
6

Glaukos headquarters in Aliso Viejo, California

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPATIENT FOCUS
GRI 2-6We are focused on addressing unmet clinical needs of large and underserved
patient populations suffering from glaucoma, corneal disorders, and retinal
diseases.

Glaucoma
Glaucoma is a group of eye diseases characterized by progressive and irreversible vision
loss in which elevated levels of intraocular pressure (IOP) are often associated with optic
nerve damage that can cause blindness.
Elevated IOP, or ocular hypertension (OHT), occurs when aqueous humor is not circulating
normally or properly draining from the front part of the eye, called the anterior chamber.
People with OHT are at increased risk for developing glaucoma. Primary open-angle glaucoma is the most common form of the disease. It is a lifelong condition that accounts for atleast 90% of all glaucoma cases, according to the Glaucoma Research Foundation.
There is no cure for glaucoma and controlling IOP is the only known treatment. In fact,
landmark clinical studies have confirmed that low IOP is associated with reduced
progression of optic nerve damage and visual field defect.

Corneal ecstatic disorders are a class of diseases characterized by an ecstatic, or
misshaped, cornea. This is typically caused by a weakening of the cornea due to genetic
causes, adverse side effects from ophthalmic refractive procedures such as LASIK,
excessive eye rubbing, or other factors.
Keratoconus is a type of corneal ectasia characterized by corneal thinning and bulging.
Keratoconus is a serious, sight-threatening disease and the leading cause of full-thickness
corneal transplants in the United States.

Without effective treatment, one in five progressive
keratoconus patients may require a corneal transplant,
according to research.
Sadly, as disease onset is often in teenage years, keratoconus patients may require multiple transplants over their lifetime. Keratoconus remains vastly undertreated due primarily
to underdiagnosis and the historical lack of an effective solution.

Retinal Diseases

The Centers for Disease Control (CDC) estimates that about
three million people in the United States have glaucoma,
and it is the second -leading cause of blindness worldwide.
Prescription eye drops can be effective at managing IOP, but rates of patient noncompliance with these topical medications are high due to chronic side effects, instillationdifficulties, cost, non-adherence to complex dosing regimens, and other issues. Because
there are often no early symptoms, many people with glaucoma do not know they havethe disease. For this reason, glaucoma it is often called the “silent thief of sight.”
According to the CDC, anyone can get glaucoma, but certain groups are at higher risk,
including African Americans over age 40, all people over age 60, people with a family
history of glaucoma, and people who have diabetes.

Corneal Disorders
The cornea, the eye’s outermost layer, is a clear, dome-shaped surface that functions best
as a lens when it is strong and shaped properly. The cornea is responsible for the majorityof the eye’s total focusing power, and corneal disorders, including ectasia, refractive vision
errors, and dry eye, among others, can cause vision impairment.
7

Retinal diseases vary widely but universally affect the retina, a thin layer of tissue inside theback wall of the eye containing light-sensitive cells that convert light into neural signals.
Most retinal diseases cause visual impairment, including blurred or distorted vision, andvision loss.
Age-related macular degeneration (AMD) is a progressive disease that occurs when themacula, the central portion of the retina, is impaired, which can result in severe vision
problems.

According to Johns Hopkins Medicine, risk factors for
AMD include being 50 and older, smoking, having highblood pressure, and eating a diet high in saturated fat.
Diabetic macular edema (DME) is highly prevalent among individuals with type 2 diabetes
and is associated with diabetic retinopathy (DR), the impairment of small blood vessels in
the retina caused by increased glucose levels. Advanced DR can lead to fluid leaking into
the macula, which causes DME and severe vision impairment. Retinal vein occlusion (RVO)
occurs when the flow of blood from the retina is blocked, often due to a blood clot
blocking the retinal vein, which can result in severe vision problems.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXNOVEL PLATFORMS
GRI 2-6We continue to successfully invest in and advance our robust pipeline of novel, promising
platform technologies that we believe canprovide significant new treatment options for patients
while expanding our addressable markets and fundamentally transforming our Company over time.
Our platforms embody ambitious, big ideas that challenge conventional thinking and strive to overcome theshortcomings of traditional treatment paradigms. We
believe they have the ability to generate a robust cadenceof new products over the coming years that can generate
layers of future growth.
We currently have 14 publicly disclosed pipeline
programs, which represents a significant increase vs. ourdisclosed pipeline program count (four) in 2015, when we
became a publicly traded company.

The following is a summary of our platforms. More information is available in the Product Innovation section of thisreport and in our Quarterly Summary.

GLAUCOMA PATIENT FEEDBACK“Glaucoma is a scary thing.
It’s a silent, sort of, invasion
and I want people to knowthat there is something thatyou can do about it.

iStent Platform
Through our foundational iStent micro-surgical platform,
we are pioneering a new treatment for glaucoma — MicroInvasive Glaucoma Surgery (MIGS). This platform includes
an array of devices designed to reduce IOP by restoring
the natural aqueous humor outflow pathways for patients
suffering from glaucoma.
We believe our iStent portfolio is the industry’s most comprehensive offering of minimally invasive, tissue-sparing
glaucoma solutions. It is designed to provide a full range
of options to fit surgeons’ individual treatment algorithms
for every stage of disease progression, from OHT through“I would encourage people
to look into how they canlower their eye pressure thesame way I did.”-George G., iStent inject® W patient, North Carolirefractory disease, and in both combo-cataract andstandalone procedures.

FIVE DISTINCT TECHNOLOGY PLATFORMS

Through our platforms, we are working to
disrupt conventional topical eye drop therapies
with dropless alternatives that will offer important
benefits to patients and physicians.
Our five key technology platforms are designed
to generate a cascade of therapies over the next
decade to address significant unmet clinicalneeds.

We are proud to be the corporate pioneer and global
market leader in MIGS, with our family of iStent technologies supported by approximately 300 peer-reviewed
publications, more than 20 years of clinical and commercial experience, and more than a million iStent devices
implanted worldwide since our inception.

iDose Platform
Our iDose sustained-release procedural pharmaceuticalplatform consists of targeted, minimally invasive,
injectable implants designed to deliver therapeutic levelsof medication from within the eye for extended periods oftime. It is designed to address ubiquitous patient nonadherence and chronic side effects associated with topical
medications by providing 24/7, long-duration, robust
efficacy with minimal side effects.
In December 2023, we were delighted to announce FDA
approval of iDose TR, our revolutionary, micro-invasive,

8

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXNOVEL PLATFORMS
injectable therapy designed to lower IOP in patients with
open-angle glaucoma or OHT.
iDose TR is a first-of-its-kind intracameral procedural pharmaceutical designed to deliver glaucoma drug therapy for
up to three years.

The iDose TR was designed to usher
in a new era of interventional
glaucoma by enabling a proactive
approach with a safe, effective, anddurable therapy for patients in need.

With the commercial launch of iDose TR, we are pioneering a brand-new category of procedural pharmaceuticals
that has the potential to reshape glaucoma management
as we know it today. We are excited to now bring thistransformative technology to market and, in doing so,
expand the treatment alternatives for the full range ofglaucoma disease severity.
Given our development success to date with iDose TR, we
continue to invest resources to develop future iDose
solutions.

iLink® Platform
Our iLink bio-activated pharmaceutical platform consistsof novel single-use drug formulations that are bioactivated by our proprietary systems. These systems
deliver ultraviolet light to the cornea to induce a biochemical reaction called corneal cross-linking designed tostrengthen, stabilize, and reshape the cornea.
Even though keratoconus is a serious sight-threatening
disease and the leading cause of full thickness corneal
transplants in the U.S., we believe it remains vastly
9

KERATOCONUS PATIENTFEEDBACK“The iLink treatment
has been worth it forme.
Knowing that I won’t
need to have multiple
procedures or get abrand-new prescription
for glasses every
couple of months is amassive quality of life
improvement.”-Joseph C., iLink patient, California

investments and executed upon a number of strategies
designed to expand our commercial organization, lower
the barriers for adoption by practices, increase awarenessof keratoconus across the optometric and ophthalmic
community, streamline the referral patterns, and train
corneal health professionals on our iLink procedure.

iLutionTM Platform
Our iLution transdermal pharmaceutical platform, which
consists of patented, cream-based drug formulations, areapplied to the outer surface of the eyelid for droplessdelivery of pharmaceutically active compounds for thetreatment of eye disorders. We believe iLution’s differentiated delivery approach on the eyelid may offer significant
advantages over traditional topical delivery, including thepotential for easier administration, faster onset of action,and fewer side effects, such as reduced preservative
induced corneal and conjunctival sequalae, all of which
can help contribute to better compliance and improved
patient outcomes.

Retina XR Platform
undertreated. This undertreatment is due primarily tounder-diagnosis and the historical lack of an effective
solution.

iLink is the first and only FDAapproved corneal cross-linking
procedure that slows or halts the
progressions of keratoconus andhelps preserve vision.

Our bio-erodible sustained release pharmaceuticalplatform, known as Retina XR, is designed to treat retinal
diseases, the largest market in ophthalmology today.
The goal of these investigational programs is to provide
retinal specialists and their patients with novel sustained
pharmaceutical treatment options that offer ameaningfully longer duration-of-effect than the current
standard of care dominated by short lasting biologicalinjections that often impose tremendous treatment
burdens on patients because of the high-frequency of
required treatments.

In order to maximize the availability of this important
Photrexa therapy for patients, we have made substantial
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXSUSTAINABILITY
We continuously review our sustainability
program and policies throughout the year. In
2023, we focused on initiatives aligned with ourbusiness strategy, achieving established goals
and setting new goals, peer benchmarking,applicable ratings and rankings gap analysis,
engaging with stakeholders, and maturing ourdisclosure.
GRI 2-9; GRI 2-13

Every year we engage in a substantive conversation with our shareholders to better
understand their expectations regarding our environmental, social, and governanceefforts. For the past seven years, including 2023, we have engaged with more than 60%
of our outstanding common stockholders. Their feedback is critical to our environmental, social,governance, and executive compensation design and we take action each year in response tothis outreach. More information about our outreach efforts, stockholder feedback, and responsive
actions taken can be found in our Proxy Statement.
Additionally, every board member as well as certain members of senior management received
sustainability updates through our corporate membership with the National Association of
Corporate Directors.

Sustainability Governance
We are diligent in ensuring proper oversight of our sustainability program. Our Board of
Directors oversees the adoption and implementation of our sustainability initiatives. The Board's
Compensation, Nominating, and Governance Committee updated its Committee Charter on
December 17, 2020, to formalize its responsibility for oversight of sustainability matters. The
Committee receives quarterly updates on our progress and reports the information to the full
Board. Please visit the Compensation, Nominating, and Governance Committee Charter and our
Proxy Statement for more information.
10

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPROGRAM DESIGNGRI 2-9; GRI 2-13; GRI 2-14; GRI 2-29; GRI 3-1; GRI 3-2

Sustainability Council
In addition to Board-level sustainability oversight, we formed the Glaukos
Sustainability Council in late 2020, a
task force of cross-functional subject
matter experts, to lead the formulation and implementation of sustainability policies and programs undermanagement’s direction. The

Sustainability Council’s first undertaking was to research and evaluate thevarious sustainability topics to prioritize Glaukos’ goal-setting process
and disclosure framework.

Prioritization
In early 2021, we identified “Tier 1”
topics, which we consider the mostimportant to stakeholders. These
topics, which have the highest
potential impact on Glaukos’
business success, are the focus of
our sustainability management, goal
setting, and reporting.
While we consider each topic to beimportant to our success, it is imperative that we allocate resources to

TOPIC PRIORITIZATION PROCESS
Identified 39 total topics: Reviewed 20 varied
sources to identify universe of potential topics

23 TOPICS SURVEYED AND
ANALYZED
Governance• Climate Strategy• Cybersecurity and Data Privacy• Ethics and Compliance• Executive Compensation• Geopolitical Disruption• Political Participation and Advocacy• Protection of Intellectual Property• Responsible Procurement Practices• Risk Oversight• Transparent Communications and Reporting

Products
Refined to 23 topics: Conducted enterpriserisk assessment to continue refining topic
list; used 23 of these topics as subjects ofstakeholder surveys and other analysis
Evaluated internal sources: Reviewed multiple internal sources (management and employee surveys, strategic plan, foundationrelated strategy document, etc.) and continued to narrow list to focus on topics withgreatest potential impact on Glaukos’ business success
Evaluated external sources: Analyzed customer perspective research, investor engagement
feedback, analyst prioritization, and peer topic benchmarking to identify the top Tier 1 material topics
11• Access, Affordability, and Pricing• Product Innovation• Product Quality and Patient Safety• Transition from Research to PracticeSocial• Diversity and Inclusion• Human Rights• Philanthropy and Volunteerism• Talent Attraction, Development, Engagement, andRetention• Workforce Health and Safety

Environmental• Energy and Emissions• Sustainable Product Design and Packaging• Waste• Water
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPROGRAM DESIGN
those topics that will have the most impact on Glaukos’ business and drive shareholder
value. Although none of our Tier 1 topics fall into the Environmental category, we willcontinue to report on environmental matters. It is important that we maintain public
accountability for our energy and water use, waste creation and disposal, and climate
impact and strategy.

Evaluation and Goal Setting
After identifying our Tier 1 topics, we assigned responsibility for each topic to the most
relevant member of the Sustainability Council, based on their role and responsibilities.
For example, our Senior Vice President, Operations, is the topic owner of Responsible
Procurement Practices. The topic owners assume responsibility for reviewing ourmanagement approach for each Tier 1 topic and identifying improvement opportunities.
At the end of each calendar year, we hold Sustainability Council meetings to propose,
discuss, and set new goals. Topic owners review the SMART (Specific, Measurable,
Achievable, Relevant, and Timebound) goal criteria to prepare for our annual goal-setting
workshop. During the workshop, we create draft goals for each topic area.

We continue our regular Sustainability Council meetings throughout the year to supportand review progress toward our goals. Our goals include annual and time-bound goals.
The goals for each Tier 1 topic are set forth here. We report annually on our progress
toward these goals. The goals may be adjusted or expanded as we continue to refine oursustainability program. This report reviews Glaukos’ Tier 1 sustainability topics, how wemanage them, and the steps Glaukos plans to take to demonstrate continuous improvement. The topics have been grouped by category — Governance, Products, Social, andEnvironmental.

SUSTAINABILITY COUNCIL

Once the Council agrees on the updated goals, the Sustainability Committee co-chairspresent the draft goals to senior management for final approval. The goals are thendiscussed with the NCG Committee of the Board prior to publication.

TIER 1 SUSTAINABILITY TOPICS
CEO Tom Burns (second from left) and the Sustainability Council members gather in June
2023 to celebrate achievement of key sustainability goals.

12

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPROGRAM DESIGNTOPICGOALS SET IN 2024 (Where no year is mentioned, the goal is an annual goal to be pursued ad infinitum.)

GOVERNANCE
Completion of anti-bribery/anti-corruption training by 100% of new or renewing distributors and applicable new hires
Ethics and Compliance

Annual certification by 100% of employees regarding compliance with Code of Business Conduct and Ethics
Review and refresh Code of Business Conduct and Ethics in 2024
Update R&D design development documents to require evaluation of sustainability in product design and packaging

Responsible Procurement
Practices

By 2027, change from paper IFUs to electronic for all medical devices (where permitted by regulation)
Conduct engineering evaluation of conversion to biodegradable Corneal Health packaging in 2024

Cybersecurity and Data Privacy

By 2025, formally track alignment of the information security program to relevant components of the NIST security framework based upon risk to Glaukos and industry best practices

PRODUCTS
Product Quality and Patient Safety

Product Innovation

Zero product recalls
100% of employees complete Product Quality training
FDA submissions of pipeline technologies that would allow us to meet our publicly stated targets for FDA approvals
Advancement of key clinical programs
By 2024, help >5,000 patients navigate their keratoconus treatment journey
Establish process to make iDose accessible to underserved communities via the iDose Your Dose global program

Access, Affordability, andPricing

In coordination with patient advocacy organizations, support patients with educational materials to build awareness of early intervention, find community, and manage their disease
By 2025, provide a comprehensive range of services to U.S. patients and caregivers enrolled through a healthcare provider or self-enrolled to support the critical phase of early decisionmaking about their keratoconus or glaucoma care
By 2027, develop a team of Patient Ambassadors to educate U.S. patient and advocacy organizations.
By 2030, surpass 10,000 cumulative stent donations and 150 recipient organizations

SOCIAL
Talent Attraction, Development,
Engagement, and Retention

Diversity and Inclusion
Workplace Health and Safety

Based on this year’s Great Place to Work engagement survey results, identify areas of opportunity; communicate and measure progress against improvement areas in the following year
Continue the strategic expansion of leadership and employee development activities with pilot launch of at least three leadership and employee development activities
As led by our DEI Forum, continue to expand Glaukos’ approach to diversity, equity, and inclusion in 2024
Develop strategic and intentional recruitment outreach efforts to diverse candidates
Conduct an annual Health and Safety risk assessment and implement at least one new initiative annually to mitigate the top risk identified

ENVIRONMENTAL
Maintain ISO 14001 Certification for San Clemente and Burlington sites

Establish standard design guidelines for new facilities to evaluate energy efficiency and other environmental considerations

13

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIX

GOVERNANCE
Glaukos is committed to responsible
management of our business. Proper governanceensures that we are operating in a manner toensure long-term business success.

GOALS SET IN 2023

ETHICS ANDCOMPLIANCERESPONSIBLE
PROCUREMENT
PRACTICESCYBERSECURITY
AND DATA PRIVACY
14

Completion of anti-bribery/anti-corruption training by 100% of new
or renewing distributors
Annual certification of Code of Business Conduct and Ethics by 100%of employees

In 2023, reduce percentage of Glaucoma medical device producttransported via air by developing 2nd site distribution center (2021 asbaseline)

YE 2023
STATUSGOALS SET IN 2024

Completion of anti-bribery/anti-corruption training by 100% of new orrenewing distributors and applicable new hires
Annual certification by 100% of employees regarding compliance with
Code of Business Conduct and Ethics
Review and refresh Code of Business Conduct and Ethics in 2024
Update R&D design development documents to require evaluation ofsustainability in product design and packaging
By 2027, change all medical devices from paper IFUs to electronic(where permitted by regulation)

In 2023, convert Corneal Health Photrexa® cross-linking kits’ packaging and shipment materials to biodegradable materials, reducing
waste and implementing cost savings

Conduct engineering evaluation of conversion to biodegradable
Corneal Health packaging in 2024

By 2025, formally track alignment of the information security program
to relevant components of the NIST security framework based uponrisk to Glaukos and industry best practices

By 2025, formally track alignment of the information security program torelevant components of the NIST security framework based upon risk to
Glaukos and industry best practices
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXETHICS AND COMPLIANCE
Ensuring training and policies are in place to promote ethical behavior, including compliance with all relevant laws and regulations
GRI 2-15; GRI 2-23; GRI 2-25; GRI 2-26; GRI 3-3; SASB HC-BP-260a.2; SASB HC-MS-270a.2; SASB HC-BP-270a.2; SASB HC-BP-510a.2; SASB HC-MS-510a.2

Glaukos seeks to foster a workplace culture that values integrity and ethical conduct
to ensure that we are respected and trusted by our customers, peers, current andprospective employees, and investors. By conducting ourselves in a compliant
and ethical manner, Glaukos can increase the trust and goodwill of our stakeholders, create a working environment in which employees are engaged and proud to work for us,
avoid the cost and time required to address problems arising from noncompliance, andensure that our team can remain focused on creating transformational products.

Management Approach
Acting in an ethical and compliant manner, both with respect to internal policies and external laws and regulations, is an integral part of every decision we make. Glaukos policies
are intended to help our employees understand the importance of acting ethically to uphold our reputation of respect, trust, confidence, and integrity.

EMPLOYEE FEEDBACK

We implemented the Glaukos Compliance and Ethics Program to help us comply withstate, federal, and international regulations and to provide guidance on interactions withhealthcare professionals and governmental entities. The Program also helps us manage
compliance-related risks. The Company’s Chief Compliance Officer leads the Complianceand Ethics Program and reports to the Audit Committee of our Board of Directors
quarterly. The Chief Compliance Officer also chairs the Glaukos Compliance Committee,
comprised of senior representatives from Legal, Governance, Commercial, Operations,
Finance, Human Resources, and Internal Audit. The Compliance Committee advises andassists with the implementation of the Compliance and Ethics Program.
As part of the Compliance and Ethics Program, Glaukos adopted policies and procedures
which serve as written standards of conduct for our employees. These policies include,
among others, our Code of Business Conduct and Ethics, our Code of Ethics on Interactions with U.S. Health Care Professionals, our U.S. Foreign Corrupt Practices Act (FCPA)/
Anti Bribery Policy, our Internal Investigations Policy, our State and Local Compliance
Registration and Reporting Policy, our International Transparency Reporting Requirements
Policy, and our Insider Trading and Tipping Policy. These policies and procedures arereviewed and updated regularly.

“Glaukos has a true open-door policy. I would be completely
comfortable talking to someone at all levels of theorganization.”

Anti-bribery and Corruption training was completed by“Our executives and Senior Leadership Team lead by example
and take the time to get to know people at all levels.”

third-party distributors in 2023.

-Participants in Glaukos’ 2023 Great Place to Work employee
survey15

100% of applicable employees and all new and renewing

The Compliance and Ethics Program also defines our efforts to annually monitor, audit,
and evaluate compliance with our Code of Business Conduct and Ethics and supporting
policies and procedures, including efforts to monitor the activities of our sales force, marketing teams, and all other personnel who interact with healthcare professionals. The nature of our reviews and the extent and frequency of our compliance monitoring vary according to factors such as new or amended legal and regulatory requirements, changes inbusiness practices, and other risk considerations. We also monitor all reports of noncompliance made to our employee hotline. Please visit the Reporting Hotline section for more
information.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXETHICS AND COMPLIANCE
As part of the Compliance and Ethics Program, we have disciplinary action guidelines tofollow when an employee violates internal policy or external regulation. We assess
violations to determine if they resulted from gaps in our policies, practices, or internal
controls and make internal adjustments to prevent future violations. Our disciplinary
guidelines are intended to help us maintain a consistent approach to disciplinary actions,which can be as severe as termination. Externally, Glaukos complies with the Drug Supply
Chain Security Act (DSCSA). Through this regulation, Glaukos is required to report any
potential counterfeit products to the Criminal Division of the U.S. Department of Justice.
In late 2023, we performed a gap assessment to identify areas to enhance and further
develop our Compliance Program. We are incorporating the identified areas into our2024 Compliance Plan, designed to further mature and enhance the integrity andcompliance of our Company.
As part of our annual Compliance Plan, in 2023, we implemented several new policies,
procedures, and guidelines, launched a new reporting hotline and associated casemanagement system, implemented a distributor management system, added web-based

CODE OF BUSINESS CONDUCT AND ETHICS
Our Code of Business Conduct and Ethics has been translated into several local
languages for our international employees and covers a number of critical
topics, including:•

Reporting Violations of the Code
Policy Against Retaliation
Conflicts of Interest
Confidential Information Handling
Competition and Fair Dealing
Appropriate Business Practices Relating to Gifts and Entertainment
Handling of Company Records
Protection and Use of Company Assets
Accuracy of Financial Reports and Other Public Communications
Compliance with Laws and Regulations
Maintaining the Health and Safety of the Company’s Environment and Workforce
Political Contributions and Volunteer Activities
Anti-bribery and Corruption•

Public Communications

•
•
•
•
•
•
•
•
•
•
•
•

16

automation to our U.S. transparency tracking methods and centralized our internationaltransparency reporting process, created a cross-functional investigators tool kit, and expanded our physician engagement system controls.

Policies
Our policies communicate that a culture of integrity is an asset. Our Code of BusinessConduct and Ethics serves as a standard for Glaukos employees, officers, and the Boardof Directors. It covers topics such as non-retaliation, conflicts of interest, compliance, andanti-bribery and corruption. Noncompliance with the Code poses a significant financial
and reputational risk.
The Code of Business Conduct and Ethics also prohibits employees from using Company
funds or assets for political purposes unless approved by the Chief Compliance Officer. In
the interest of advancing sound public policy, we support those persons who serve thepublic by seeking elected office. Consistent with U.S. federal and state laws, Glaukos
established the Glaukos Political Action Committee (Glaukos iPAC) in 2023, funded solely
through employee contributions. Glaukos iPAC offers eligible U.S. employees a directmeans to voluntarily participate in shaping sound public policy and voicing views on
issues related to our business.
Our Anti-Bribery Policy defines corruption and prohibits the making of bribes or facilitation payments. In 2023, we conducted an enterprise risk assessment, which includes areview of the likelihood of bribery and corruption risks within the organization and theeffectiveness of controls in place to mitigate these threats.

Training
Glaukos conducts in-person and online training on our policies and procedures, including
Code of Business Conduct and Ethics principles, ethical interactions with healthcare
professionals and payors, promotional communications, reporting violations, transparency
reporting, privacy, and anti-corruption. We update our training programs based on theimplementation of new policies and guidelines, monitoring and investigation findings,
emerging risks, and new legal and regulatory requirements. This training includes
Company personnel and certain third-party business partners, such as distributors andlogistics providers.

Healthcare Professional Interactions
At Glaukos, we recognize that interacting with healthcare professionals is essential todevelop innovative products and to provide vital education and training on our ophthalmic treatments and therapies. Our interactions with healthcare professionals must comply
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXETHICS AND COMPLIANCE
with state, federal, and international laws and regulations and satisfy ethical standards appropriate for our industry. We must also fulfill the required transparency
reporting related to those dealings. The Company has adopted policies and procedures intended to set rules regarding our interactions with healthcare professionals
and establish the process for reporting payments and other transfers of value in thejurisdictions in which it is mandated, including our Code of Ethics on Interactions
with U.S. Health Care Professionals, our State and Local Compliance Registration
and Reporting Policy, and our International Transparency Reporting Requirements
Policy. Engagement with healthcare providers is an important part of our businessso that we may convey vital information regarding our products and the diseases
they are intended to treat or so that we can gain and share knowledge from theirexpertise and experience.

Glaukos acts in accordance with the AdvaMed Code of
Ethics on Interactions with U.S. Health Care Professionals.
These policies, procedures, and related guidelines provide our employees withguidance on how to engage with healthcare providers responsibly, avoiding any
improper influence over a healthcare provider’s independent medical judgment.

Third Parties
Glaukos engages third-party distributors to sell our products in countries where we
do not have direct presence or personnel. These distributors represent Glaukos
when selling our products. We rely on them to uphold the ethical standards towhich we hold ourselves when interacting with customers. If red flags are detected,
appropriate steps are taken to prevent and/or mitigate any associated risk to theWe perform due diligence on all new and renewing
distributors and pursue enhanced inquiries on a risk -ETHICS SURVEY RESULTS
In 2023, we conducted a companywide Great Place to Work employee survey. The
survey is designed to document the opinions and attitudes of our employees withrespect to workplace culture, including how effectively Glaukos leaders exhibit ethics, compliance, and integrity. Based upon our belief that operating in an ethical andcompliant manner is vital to a strong culture and successful organization, the resultsof the survey are used to gauge where we are currently as a company and where wehave opportunities to grow and develop. The survey was conducted by a third party,
and the responses were anonymous. Approximately 83% of our employees participated in the survey.
The results demonstrated a strong influence of ethical practices within Glaukos andthat senior management places a high premium on integrity, ethical behavior, andtone at the top. This helps us understand employees’ perspectives on ethical matters, and the scores can be compared between functions and business units andwhere available, benchmarked against those of similar entities. Below are highlightsof the results.

90%

of Glaukos respondents said: Management is honest and ethical in their businesspractices.1

91%

of Glaukos respondents said: Our executives fully embody the best characteristics
of our company.2

91%

of Glaukos respondents said: I feel safe to make job-related decisions without
feeling pressure to compromise ethics, integrity or to violate policies or the law
in order to achieve business goals.3

87%

of Glaukos respondents said: Management is approachable and easy to talk with
about issues related to ethics, integrity, and doing the right thing.3

based model that considers previous infractions, suchas civil and criminal disputes and thecorruption perception index of thecountry in which the distributor isselling our products.
17

1 According to 100 Best U.S. Companies Benchmark, 92% of respondents said this. 2 According to the 100 Best
U.S. Healthcare Companies Benchmark, 88% of respondents said this. 3 No benchmark available for this metric.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXETHICS AND COMPLIANCE
Company. Our written contracts with distributors require
both parties to comply with laws, including anti-corruption
and export laws. We also assign online, interactive training
on anti-bribery and anti-corruption to all our new and renewing third-party distributors.

Glaukos also engages U.S. health care professionals toprovide legitimate consulting services if they possess therequisite qualifications, experience, special knowledge, orcapabilities. The consulting services and related payment
rates are subject to a needs assessment approval process
and fair market value evaluation. All new and renewed
distributors and U.S. health care professional consultants
are subject to pre-engagement and ongoing sanction,
debarment, and adverse media screening.

Marketing Practices
Glaukos has adopted several marketing practices policies
and procedures, including our Code of Ethics on Interactions with U.S. Health Care Professionals, Unsolicited Offlabel and Pre-approval Medical Information Requests, andVeeva Vault QualityDocs End User Standard Operating
Procedure.

We’ve designed our policies andprocedures to ensure our marketing
materials and practices aretransparent, lawful, truthful, on-label,and not misleading.
Appropriate personnel, including sales, marketing,professional education, and market access employees,
receive training on related topics such as on-label
marketing, reimbursement and patient support activities,
Company-hosted product training and education, theprovision of meals, travel, gifts and entertainment,
Company support of third-party educational programs,18

and consulting arrangements with healthcare professionals.

determine if any retaliation has occurred. Any employee
engaged in retaliation will be subject to disciplinary action.

We also provide training to those who speak on ourbehalf, such as healthcare professionals. A cross-functional
legal, regulatory, and medical team approves written marketing materials to ensure product information is truthful,
not misleading, accurate, balanced, responsible, and consistent with approved indications and available clinical
data.

Progress Toward our Goals

Reporting Hotline
Glaukos encourages communication regarding suspectedviolations of Company policy or law. Employees can reportsuspected violations to their supervisor, Human Resources, the Chief Compliance Officer, or through ouranonymous third-party managed reporting hotline,
accessible 24/7 via the web or a toll-free number. The
hotline is available on our website to all employees,
investors, suppliers, and other interested parties and isaccessible globally in several local languages. Employees
receive email reminders about this hotline semiannually.
Through the third-party’s implemented case management
system, we track and review all reports to the hotline andinvestigate appropriately. When sufficient information ispresented to warrant an investigation, we promptly
investigate all alleged material violations of law andCompany policies.
We follow up with the reporter(s) and subject employee(s),if applicable, to share investigation results while being
mindful of the privacy rights of those involved and theconfidentiality needs of the Company. Our Code ofBusiness Conduct and Ethics explicitly prohibits any formof retaliation against an employee who, in good faith,
reports suspected misconduct.

2023 Goals

Completion of anti-bribery/anti-corruption training by 100%of new or renewing distributors
Annual certification of Code of Business Conduct and Ethics
by 100% of employees

In 2023, we reached our goal of 100% completion of antibribery/anti-corruption training by all 21 of our new orrenewing third-party distributors. We strive to achieve thisgoal again in 2024 because it allows us to emphasize to
key supply chain partners our requirement that they dobusiness in a legal and ethical manner. It also ensurescontinued access to the key materials driving our products.
We also reached our goal of annual certification of ourCode of Business Conduct and Ethics by 874 employees,
which constitutes 100% of our active employees as ofDecember 15, 2023, who did not subsequently separate
from the Company. The certification ensures that ourpersonnel understand the expectations set forth in our
Code of Business Conduct and Ethics and encourages our
employees to partner with the organization to manage ourinstitutional ethics goals. We will once again requirecertification of our Code of Business Conduct and Ethics
by all employees in 2024.
We also plan to review and refresh our Code of BusinessConduct in 2024.

At the conclusion of an investigation, we confirm that
corrective actions have been taken, and we endeavor tocheck back in with reporters or review records to
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXRESPONSIBLE PROCUREMENT PRACTICES
Providing policies for and assessing and monitoring Glaukos’ suppliers for sustainable practices including labor practices, such as human rights, fair treatment, child labor, andsafe working conditions. Making sure that the products and services procured are sustainable, with low environmental impact and positive social results
GRI 2-6; GRI 2-25; GRI 3-3; GRI 308-1; GRI 414-1; SASB HC-BP-430a.1; SASB HC-MS-430a.1; SASB HC-MS-430a.2; SASB HC-MS-430a.3

Glaukos’ delivery of vision-saving products topatients depends on our ability to source thematerials used to manufacture our products in a
responsible and sustainable manner. Through responsible
procurement practices that cultivate strong supplier
relationships, we can stimulate the global economy while
acquiring the materials needed to create life-changing
products for our customers. Further, our pursuit ofadvanced manufacturing technologies, which are essential
for meeting the precise tolerances required for our
products, are primarily found in the most developed
countries where higher standards of human rights areupheld.

of our manufacturing to third-party manufacturers, all ofwhich must be highly capable.

Management Approachbased in highly regulated countries,

Our Legal and Supply Chain teams collaborate to manage
our responsible procurement practices. The Legal team is
responsible for monitoring compliance and aligning ourpractices with laws and regulations. The Supply Chain and
Supplier Quality teams lead supplier engagement efforts
through managing primary supplier touchpoints. We use
a consistent high-level strategy to manage all our sites, butthere are tactical differences based on regional variability.
We believe that our responsible procurement practices
help promote ethical economic growth in the communities and regions in which our suppliers are located.

including the EU, the U.S., and Japan.

As a pioneer of ophthalmic devices and pharmaceuticals,
Glaukos creates unique, often micro-scale, products.
There are limited companies that can meet our technicallychallenging supply requirements; we are sometimes
tasked with teaching suppliers how to manufacture our
products properly. We do some manufacturing in-houseat our Glaukos manufacturing facilities, which maintain
International Organization for Standardization (ISO) 13485
and ISO 14001 certifications. We outsource other aspects
19

As a highly innovative company, we are constantly evaluating our internal manufacturing capacity against ourdevelopment pipeline's long-range sales forecast andcadence of new products. We do this to prepare for the
regulatory process of securing FDA site approvals. The
evaluation includes analyzing which manufacturing
processes we would like to keep in-sourced as corecompetencies and which we are willing to outsource tothird-party manufacturers.

Our critical suppliers are primarily

This results in slightly higher
manufacturing costs, but it also
contributes to increased sustainability
throughout the manufacturing process
and decreases our procurement
partners' risk of irresponsible
manufacturing.
Glaukos applies a risk-based approach to managing
critical materials by strategically storing specific work-inprogress inventory with suppliers and onsite at Glaukos
facilities. We also utilize a two-site model for finishedgoods inventory by storing a portion of products onsite at
Glaukos and the remainder with warehousers or
distributors. We set quantity and quality targets and metrics around each location where our materials are housed

to minimize risk. We follow our Quality Procedures toqualify additional distributors and govern our business
relationships.
We also manage critical materials by secondary sourcing
as needed. FedEx is our preferred logistics provider. We
renegotiate our logistics contract annually and evaluate
additional external bids regularly.
As part of our Quality Procedures, we conduct a risk
assessment on all Glaukos suppliers that considers what
they supply to Glaukos and the potential impact on our
products or services. Factors taken into consideration
include product-specific risk assessments, evaluation of
the supplier’s Quality Management System (QMS),
certification to ISO 14001, statistical reliability of delivery,
volume of production, and geographic location related
to the potential for sub-suppliers. All Glaukos suppliers
are assigned a risk level based on the risk assessment,with highest risk suppliers being our critical suppliers (Risk
Level 1), as stated in our Standard Operating Procedures.
Our Quality Team is also responsible for preparing andenforcing the audit schedule. We typically perform auditsof critical suppliers (Risk level 1) of commercial products
annually. We also audit our lower-risk suppliers of commercial products periodically based on the establishedrisk assessment. Additionally, we perform audits to qualify
suppliers and to address supplier caused problems
commensurate with risk.
During the audits, we aim to identify how our suppliers
perform against all applicable regulation standards, ISOstandards (ISO 9001 QMS and ISO 13485 Medical
Devices) and internal policies and procedures applicableto each individual supplier. For our suppliers that have
QMS, Glaukos engages with them to develop the QMS,
which includes training as a key component. We use
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXRESPONSIBLE PROCUREMENT PRACTICES
information gathered during the audits to confirm that our suppliers meet our standards
and address potential gaps and opportunities for improvement.
Glaukos sources primarily from the U.S., E.U., and Japan, all of which have high child laborand human rights standards, limiting our risk of human rights violations. Because Glaukos
utilizes materials that need to be bio-compatible, the use of copper, cobalt, lithium is also
negligible. Further, Glaukos does not source materials from high-risk regions.
We issue Supplier Corrective Action Requests (SCARs) to suppliers in which we identified
concerns during the audits and throughout the year. Issuance of a SCAR is commensuratewith risk to Glaukos. A SCAR provides suppliers the opportunity to formally document theroot cause of an issue and its remediation plans. The problem-solving process for the
SCAR includes containment/correction, root cause investigation and identification,corrective action, and verification of corrective action effectiveness.

Responsible Supply Chain Policies
We value our relationships with our suppliers and are committed to conducting businesswith suppliers who act responsibly and ethically. We adopted a Supplier Code of Conduct
and a Human and Workforce Rights Policy that outline our expectations for ourselves and

TWO-SITE DISTRIBUTION MODEL

Our standard practice is to enter into quality agreements with all critical suppliers. These
quality agreements describe the obligations and responsibilities of the parties to ensure
our products are manufactured, stored, and transported in a compliant and safe manner.
The transportation of Glaukos’ products must adhere to specific temperature-controlled
requirements. While more efficient or lower carbon shipping methods may exist, Glaukos
must prioritize modes that adhere to the necessary temperature range for transporting its
products safely.
As a manufacturer of medical devices and pharmaceutical products, we must trace our
products from the earliest manufacturing phases. We follow products from individual
product components to distribution. We maintain a well-developed traceability process,including formal recall and triage procedures, and conform to the Unique Device
Identification (UDI) requirements to ensure compliance with this obligation. Additionally,for pharmaceutical products, we utilize a third party, TraceLink, to ensure compliance with
the Drug Supply Chain Security Act (DSCSA), which serves to minimize the threat ofcounterfeiting.
Glaukos products must be packaged in a way that maintains integrity and temperature.
Additionally, Glaukos must perform Leachables and Extractables (L&E) testing for our
packaging materials to ensure packaging materials do not leach into the products.
Instability or inconsistency of packaging materials will not allow Glaukos to pass L&E
testing.
As we are FDA-regulated, Glaukos must also maintain virgin (or unrecycled) materials inpackaging. Packaging qualification requires validation out to three years consistent withproduct stability or shelf life.

20

To reduce costs and emissions for delivery of our Glaucoma device products,
we collaborated with FedEx to develop a two-site distribution model. We
utilized our enterprise resource management system, Oracle, to develop
electronic data exchanges for the second distribution site, which beganshipping in May of 2023. Between May and October of 2023, we increased
shipments from 0% up to 60% site split distribution. This resulted in reduced
freight costs and reduction of total air miles for products shipped to theMidwest and East Coast (products were shipped from second distribution sitein Tennessee instead of shipping from California).
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXRESPONSIBLE PROCUREMENT PRACTICESCOMMERCIAL SUPPLIER POLICIESPolicies are provided to each of our commercial
suppliers and affirm that we expect our suppliers to:•

Prohibit the use of all forms of forced or involuntarylabor, slavery, or human trafficking•

Adhere to minimum age provisions of applicablelaws and regulations•

Compensate employees and operate in compliance with applicable wage, work hours, overtimes,
and benefits laws and regulations•

Prohibit child labor•

Not engage in unlawful discrimination, harassment,or abuse of any kind•

Provide a safe, healthy, and sanitary work environment in compliance with applicable laws and regulations••

Report suspected violations of the Supplier Code of
Conduct either directly to us or through our reporting hotline, which was added into the code in 2022
Cooperate with us to ensure the smelters fromwhich they source operate responsibly

our partners. Glaukos provides our employees training on
both our Supplier Code of Conduct and ISO 14001.
Our Supplier Code of Conduct terms allow us to audit
suppliers’ operations and facilities to determine
compliance with the code. If a supplier cannot
demonstrate compliance, we consider terminating ouragreement or taking other remedial action. Additionally,as stated in our 2022 Conflict Minerals Report, we
determined that 332 of the approximately 344 smelters
who provide the designated minerals used in ourcommercial materials and components either do not21

source minerals in the Democratic Republic of the Congoand neighboring countries or are conformant to the
Responsible Minerals Assurance Process (RMAP).
We are engaged in discussions with the remaining
suppliers to ensure its smelters are RMAP conformant. We
also published our Transparency in Supply Chain
disclosure required by the California Transparency inSupply Chains Act of 2010 (SB 657). In 2023, we updated
our SOP to ensure that all new Risk Level 1 suppliers
complete the supplier survey form that contains sustainability criteria, including management of hazardous chemicals, establishment of policies on ethics, healthy and safe
workplaces, human rights, and conflict minerals, as wellas establishment of environmental objectives.

Progress Toward our Goals
2023 Goals

Photrexa cross-linking kits’ packaging and shipping materials to biodegradable materials while maintaining integrity and temperature, hoping to eliminate waste andpotentially reduce costs. Unfortunately, our Photrexa CXLkits biodegradable packaging was not able to maintainregulatorily specified temperatures.
In 2024, we will continue working on finding alternate
biodegradable products that meet our packaging andtransportation requirements for Corneal Health products.
We also plan to update our R&D design development
documents to include requirements to evaluatesustainability in all future product design and packaging.
Further, we have a longer-term goal to eliminate paper
instructions for use (IFUs) currently included within our
product packaging and switch to electronic IFUs for all
medical devices by 2027 to create a more sustainableproduct package and reduce manufacturing costs.

In 2023, reduce percentage of Glaucoma medical device
product transported via air by developing 2nd site distribution center (2021 as baseline)
In 2023, convert Corneal Health Photrexa cross-linking kits’
packaging and shipment materials to biodegradable materials, reducing waste and implementing cost savings

In late 2023, Glaukos began implementing the two-site
distribution model and reduced the number of air miles
for shipments of Glaucoma medical device product toend customers by increasing distribution from our 2nd
site distribution center. Devices were shipped from California to Tennessee by ground and then by air to end
customers in the Midwest and East Coast instead of by air
from California, resulting in reduced shipping costs andelimination of approximately 6.4 million air miles. This
contributed to reduced emissions associated with those
flights amounting to a total CO2 CHG emission estimatedat 1,286 tons.

In 2023, we worked on converting Corneal HealthGlaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXCYBERSECURITY AND DATA PRIVACY
Protecting data and ensuring the privacy and security of corporate, employee, patient, customer, and supplier information
GRI 3-3To advance our reputation as a trusted partner inevery aspect, Glaukos is committed to protecting
our information assets as well as the privacy of
employees, partners, customers, and patients. If we do not
manage cybersecurity well, the privacy of our stakeholders
and security of our network would be compromised. We
employ high-quality cybersecurity and privacy practices toprotect our data and our stakeholders’ data.

Management Approach
It is imperative that we have strong cybersecurity and data
privacy practices in place to protect our network andsystems, as well as internal and customer data. We
recognize the importance of maintaining the security of
our information systems and assets and have several
cybersecurity processes and controls designed to identify,
assess, and manage the risks associated with cybersecurity
threats and cybersecurity incidents.

respond should a security incident occur, each of whichwere updated last year. Incidents are investigated andanalyzed for potential impact. If impact is present, theappropriate departments, key employees, and executive
management team members are notified as part of theincident response process.
Our incident response plan coordinates the activities wewould take to respond to and recover from cybersecurity
incidents, which include processes to triage, assess theseverity of, escalate, contain, investigate, and remediate
the incident, as well as to comply with potentiallyapplicable legal obligations and mitigate potential liability
and reputational damage. If appropriate, incidents may bereported to senior management, the Audit Committee, or
the Board.

Our cybersecurity team is a part of our Information
Technology (IT) department. Our head of IT reports
directly to the CFO and provides periodic reports to the
Audit Committee on cybersecurity policies, procedures,and risk and mitigation efforts.

The cybersecurity team manages our Information Security
Program, which is focused on monitoring, mitigating, andaddressing cyber risks and information security. In orderto enhance internal expertise, members of our Information
Technology (IT) department maintain various
cybersecurity-related certifications including Certified
Information Systems Security Professional (CISSP),
Certified Information Security Manager (CISM), andCertified Data Privacy Solution Engineer (CDPSE).
We also maintain written incident response and security
policies that seek to ensure we are protected and ready to
22

Glaukos’ Security Program is structured around the industry standards
for security, including the National
Institute of Standards and Technology (NIST) and the ISO 27001
We also have specific cybersecurity risk assessment
processes that help identify our cybersecurity threat risks,
including comparing our processes to industry standards

and periodic third-party assessments of our programs. We
compare our Information Security Program with industry
standards, including the National Institute of Standards
and Technology Cybersecurity Framework (NIST CSF) andISO 27001. In addition to tracking best practice frameworks, we work with several trusted third parties to help us
review, assess, and continue to enhance our cybersecurity
program.
In 2023, we worked with external consultants to perform a
gap assessment of our cybersecurity program, the resultsof which were used to inform our risk assessment anddevelop our mitigation plans.
Glaukos applies a risk-based approach to enhance
security and reduce risk in the Company’s networks,systems, products, and information against evolving cyberthreats. Cybersecurity risks are integrated into theenterprise risk management process. The enterprise risk
management program is updated to the Board Audit
Committee on a semiannual basis.
To prevent unauthorized use of software by employees,
new software is evaluated for risk and approved by the
Software Approval Board before purchase or installation
on Glaukos systems. The Software Approval Board ismade up of cross-functional members from Quality,
Internal Audit, Information Security, Business Systems, andR&D to help determine risk and impact of any potential
newly proposed software.
It is Glaukos’ policy to protect the privacy of those who
entrust us with their personal information. We only collectand store personal information necessary for a lawful
purpose. Accordingly, we adopted a Privacy Policy thatdetails how personal information is collected and stored,
and what rights data subjects have with respect to suchinformation. The Privacy Policy can be reviewed on the
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXCYBERSECURITY AND DATA PRIVACY
Glaukos corporate website. We are committed to fullycomplying with data collection and processing requirements worldwide. This includes but is not limited to the
EU General Data Protection Regulation 2016/679 (GDPR)
and the California Consumer Privacy Act (CCPA).

Cybersecurity Training
Glaukos’ cybersecurity training and education emphasizes
user awareness, focusing on phishing, malware, and security best practices. Glaukos conducts annual cybersecurity
training for new and existing employees. We aim tocontinue this training annually.
We also conduct email phishing testing exercises to help
employees identify and safeguard against phishing attacks

100%of Glaukos users
completed annual
cybersecurity training
in 2023

deficiencies based on testing outcomes. We inform all
employees of our information security policies and makeour Glaukos Information Security Policy available to all
employees through our enterprise training system.

Progress Toward our Goals
2023 Goals

By 2025, formally track alignment of the information security program to relevant components of the NIST security
framework based upon risk to Glaukos and industry bestpractices

In 2024 and beyond, we will continue to advance andfurther mature our cybersecurity program. As part of thisprocess, we have created a list of our cybersecurity risks
and mapped them to the associated NIST controls. We
will then use software to track and manage our security
programs alignment to NIST, ISO27001, and other wellknow cybersecurity frameworks best practices andprioritize future enhancements to our cybersecurity
program.

that are routinely used by threat actors. Beginning in 2022,
we expanded this training to take a more risk-focused
approach.
Employees that fail our phishing testing at higher
frequency are assigned to a high-risk group level. These
groups are then assigned additional and more in-depth
training to help drive the effectiveness of our Security
Program by providing additional training to those who
may need more guidance.
In 2023, 100% of the employees who failed our phishingtesting completed the additional assigned training.
Information security training is adjusted to address
23

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCTS
Glaukos is focused on creating safe, innovative,
and affordable products to transform thetreatment of chronic eye disease.

GOALS SET IN 2023

PRODUCT QUALITY
AND PATIENT SAFETY
PRODUCTINNOVATION

Zero product recalls
100% of employees complete Quality Complianceand Patient Safety training
FDA submissions of pipeline technologies that would
allow us to meet our publicly stated targets for FDA
approvals
Advancement of key clinical programs

YE 2023
STATUSGOALS SET IN 2024

Zero product recalls
100% of employees complete Quality Compliance and Patient Safety training
FDA submissions of pipeline technologies that would allow us to meet our publicly
stated targets for FDA approvals
Advancement of key clinical programs
In 2024, help >5,000 patients navigate their keratoconus treatment journey

ACCESS,
AFFORDABILITY,
AND PRICING

Increase number of patients who receive assistancefrom one of Glaukos’ assistance programs

Establish process to make iDose accessible to underserved communities via iDoseYour Dose program
In coordination with patient advocacy organizations, support patients with educational
materials to build awareness of early intervention, find community, and manage theirdiseaseBy 2025, provide a comprehensive range of services to U.S. patients and caregivers
enrolled through a healthcare provider or self-enrolled to support the critical phase ofearly decision-making about their keratoconus or glaucoma care
By 2027, develop a team of Patient Ambassadors to educate U.S. patient andadvocacy organizations

By 2030, surpass 10,000 cumulative stent donations and 150 recipient organizations
24

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT QUALITY AND PATIENT SAFETY
Providing patients with safe, durable products that are controlled to meet high-quality standards. Clearly and swiftly disclosing information on product recalls. Incorporating
patient feedback into product innovation
GRI 3-3; GRI 416-1; GRI 416-2; SASB HC-BP-250a.1; SASB HC-BP-250a.2; SASB HC-BP-250a.3; SASB HC-BP-250a.4; SASB HC-BP-250a.5; SASB HC-MS-250a.1; SASB HC-MS-250a.2; SASB HC-MS250a.3; SASB HC-MS-250a.4; SASB HC-MS-410a.2

Glaukos is committed to developing and marketing safe, high-quality products totreat glaucoma, corneal disorders, and retinal diseases. Effective treatment ofchronic eye diseases hinges upon excellence in product design and development
to ensure robust and reproducible manufacturing processes that enable exceptional
patient outcomes and patient safety. Without careful attention to critical quality attributes,
a product could fail to meet the intended effectiveness or result in patient harm, up to andincluding the potential loss of sight. For that reason, Glaukos is focused on excellence inour product design, manufacturing, and supply chain management, optimizing
performance and patient outcomes.

QMS TRAINING

Management Approach
Glaukos assures excellence in product quality through our QMS. Our QMS entails aneffective and independent quality organizational structure, Quality Manual, policies,
operational guidance documents, robust processes, and sufficient resources to effectively
deploy and oversee compliance to our QMS. Glaukos maintains Medical Device Single
Audit Program (MDSAP) ISO 13485, the EU full QMS ISO 13485 and EU Medical Device
Directive (MDD) (CE mark) certificates for its applicable products. Our Quality Assurance
teams closely monitor our suppliers, incoming materials, in-process manufacturing, andfinished products to ensure that released products meet all established quality and safety
specifications. Our Quality Engineers work to ensure all design elements, supplieroversight, and software systems operate in a state of control.
Glaukos continues to invest in our QMS, assessing the systems used across our sites andmoving forward in the next stage of integration. Glaukos strives to optimize complianceefforts and is progressing toward alignment on a single, common platform across our sites
for several QMS elements.

Employee training is a key factor in successfully implementing the QMS. All
Glaukos employees receive comprehensive, ongoing training throughout theyear specific to their role to ensure they uphold the highest quality and safety
standards. Employees undergo periodic retraining that requires learners todemonstrate their comprehension and capability. Glaukos uses a combinationof traditional and on-the-job training to provide employees with a well-rounded
understanding of their roles.

In preparation for the new drug product application for iDose TR, Glaukos QMS was
upgraded with new software tools, experienced Quality personnel with both
pharmaceutical and combination product experience, and additional systems that
address the unique pharmaceutical regulatory expectations.

integration with Oracle PLM, and integration with the Maximo asset management software. In 2023, Glaukos updated its Quality internal audit program to ensure regularexternal product/service safety audits were assessed yearly using a risk-based approach.
Collectively, these optimizations enhance efficiencies and make sustaining regulatorycompliance simpler.

In 2022, Glaukos deployed a new, custom-configured TrackWise Digital platform tomanage many of the key QMS elements of a hybrid pharmaceutical and medical device
QMS. In 2023, Glaukos made further updates to the TrackWise Digital Platform. Thisenhancement provided a number of improvements, including automated notifications,

In 2022, Glaukos successfully harmonized the complaint management process for
Glaucoma and Corneal Health by establishing a global call center to intake customer
complaints, adverse events, medical information requests, and other customer feedback.

25

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT QUALITY AND PATIENT SAFETY
With this, in 2023, Glaukos was able to streamline the intake of inquiries, complaints,
adverse events, and customer feedback to ensure prompt and timely investigation. In
2023, Glaukos saw a reduction in investigation times, resulting in improved metrics while
ensuring timely customer responses. In 2023, Glaukos further enhanced the complaint
management system by adding fields to better analyze the complaint data. Investments in

iDOSE MANUFACTURING FACILITY

systems, processes, and training enabled our ongoing 100% on-time regulatory reporting
obligations even while the product portfolio continues to grow.
In 2022, Glaukos enhanced the quality training management system by increasing visibility
to training compliance through dashboards and reports. This improved the overall
useability of the system for trainees and yielded improvements in timeliness and compliance with quality training requirements. In 2024, we will seek further advancement in
training effectiveness and enhanced learning opportunities and growing technical andcompliance knowledge across the organization.
In 2023, Glaukos implemented Veeva Vault QualityDocs (QD) as the global document
management system. Veeva Vault QD is used as Glaukos’ document management systemfor creating, maintaining, viewing, retrieving, and storing controlled documents. With thistool, Glaukos is well-positioned with a scalable, compliant platform that will serve our
employees across the organization for years to come.
Glaukos currently performs several in-house analytical tests using robust, validated
analytical methods. We rely on qualified third-party laboratories to test the remaining
samples for raw material acceptability, finished product stability, environmental
monitoring, and product microbiological testing. As our business continues to grow, sodoes the demand for more analytical and microbiological testing, which is why we are
expanding our in-house testing capabilities. Glaukos continues to invest in and grow ourin-house analytical and microbiological laboratories and the automated technologies
necessary to assure strong data integrity.

In 2023, Glaukos completed the expansion of its San Clemente manufacturing
facilities in preparation for FDA approval and commercial launch of iDose TR, arevolutionary, micro-invasive, injectable treatment for the full range ofglaucoma severity. The expansion included the addition of dedicated rooms
for drug formulation and filling and required development of highly innovativeequipment and processes designed to overcome the challenges of handlingmicro-size devices and drug fill, such as precision micro-fluidic dispensing
equipment and proprietary drug micro-container closure equipment.
Encompassing approximately 134,000 square feet of manufacturing,
warehouse and office space, the state-of-the-art facilities are fully operationaland compliant with appropriate regulatory, CMC and ISO 7 guidelines.
26

In 2022, Glaukos began construction on a substantial laboratory expansion that
doubled our available square footage and increased our capacity to perform in-house
testing. We purchased additional analytical instruments that were qualified when the
expansion was completed in 2023. With these investments, Glaukos has completed theequipment/instrumentation installations, qualifications, and analytical method transfers
necessary to reduce turnaround time for sample testing, reduce costs associated withrequired testing, and reduce the environmental impact of routine sample shipments tovarious external qualified testing centers.
As planned, in 2024, the Glaukos Quality Control Laboratory will expand internal testingof key raw material, in process, and finished product testing, where appropriate, thereby
reducing our costs per test and turnaround time on results reporting and reducing theenvironmental burden of shipping samples from each incoming raw material and finishedgoods batches to various third-party laboratories for testing.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT QUALITY AND PATIENT SAFETY
Post-Approval Quality Management
Exceptional patient outcomes and safety are our primary focus. We provide validated
pathways for patients or clinicians to report any complaint or adverse event to our team of
medically trained professionals. These same systems are used by distributors, field service
personnel, and our sales teams to efficiently capture all the essential information thatenables Glaukos to thoroughly investigate reports and ensure all necessary actions aretaken. A few examples of these actions include, but are not limited to, advancing productdesign, further optimizing the materials used in the construction of our products,
enhancing manufacturing processes to prevent or reduce the likelihood of recurrence,enhancing our robust surgical training program, and ensuring clarity of labeling and instructions for use.

Glaukos has established a reputation for exceptional
patient safety. Based on the detailed analysis of the post marketing surveillance data for 2023, that successcontinues. In 2023, there were no significant negative
trends in patient safety observed for Glaukos ’ portfolio of
products.
Glaukos hosts several routine inspections by governing health authorities to ensure ourprograms comply with applicable regulations. In 2023, Glaukos demonstrated ourcontinued commitment to compliance with all applicable governing bodies throughsuccessful inspection outcomes. Inspections by regulatory bodies of Glaukos’ Quality
Management System concluded no incidents of non-compliance with establishedregulations for our post-marketing surveillance programs. We use customer feedback andclinician use experiences, in addition to reported patient and clinician safety information,
to improve our products and, ultimately, patient safety. Glaukos invests in tools to capture
customer feedback and analyze the data.
True to our mission, we use the data to assess and improve existing product designs andnext-generation products, ensuring ongoing innovation in product development forchronic eye diseases. Glaukos continued improving our global patient safety signal
detection system designed to analyze customer feedback and patient safety data in all themarkets we serve. While we currently carefully monitor and report on this data, this is a
critical element of our post-market surveillance and patient safety programs.
Glaukos will continue to assess ways in which this data extraction can be further
27

PATIENT SAFETY STATISTICS
Glaukos has established a reputation for exceptional patient safety. Based on
the detailed analysis of the post-marketing surveillance data for 2023, thatsuccess continues. In 2023, there were no significant negative trends in patient
safety observed for Glaukos’ portfolio of products.

Zero product recalls or fatalities related to products
Zero products on the FDA’s MedWatch Safety Alerts
Zero FDA enforcement actions taken in response toviolation of cGMP
100%: Percentage of significant product and service
categories for which health and safety impacts are assessed
for improvement

automated to allow us to streamline existing global statistical trending activities andfocus time spent on analysis and executing data-driven, value-added enhancements. From
the first stages of R&D, we use design controls to minimize the risk of product defects. If
we find a defect, R&D collaborates with our engineering team to remedy the issue. By
embedding product quality into every stage of our design process, we can detect andaddress flaws early and mitigate long-term risks. We also continuously assess the usability
and efficacy of our products as part of a robust, sustaining engineering program.
We perform formative evaluations early in the product's life cycle and summative studies
on commercial-ready products considering safety, usability, and efficacy. We also use
market feedback to optimize product design. Market data is continually reviewed toensure the continued safety and efficacy of Glaukos products that are commerciallydistributed.
Medical complaints undergo an extensive evaluation process, including gathering
information from the complainant, physician, patients, and any other relevant parties.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT QUALITY AND PATIENT SAFETY
Once we complete the assessment, we evaluate the complaint for “reportability.” If
appropriate, we report itto the FDA as a Medical Device Report (MDR) or include itin the Periodic Adverse Drug Experience Report, an electronic report filed with the FDA quarterly for the first three
years after a drug is approved and annually thereafter.
Glaukos is committed to providing the highest-level
customer experience, including effectively managing
complaints. We track and thoroughly investigate every
product complaint we receive as part of our quality
management system and medical safety infrastructure.
The company has implemented a fully functional
complaint management program that adheres to allpharmaceutical and device regulatory requirements in
the global markets in which we distribute our products.
In collaboration with the regulatory authorities, Glaukos
would notify impacted customers and provide written
information on the event and instructions on
recommended actions. Actions may include providing
clinicians and patients with additional information,
performing a corrective action on the product, or
clarifying labeling, or, when appropriate, requesting the
product be returned to Glaukos.

While Glaukos has had zero recalls,
should the need arise, we have an
established process to promptly
evaluate, document, and executeactivities are complete and health authorities are satisfied
with the actions taken, the recall will be closed.

Progress Toward our Goals
2023 Goals

Along with any necessary field actions, Glaukos would
conduct a thorough investigation into the event’s root
cause and identify corrective actions that will reduce or
prevent the likelihood of recurrence of the issue. We
actively work to optimize our QMS and manufacturing
processes to improve the quality and safety of our
products continuously, and we demonstrate the effectiveness of our QMS through favorable comparisons against
peers in the industry (e.g., the FDA MAUDE database and
FDA published recall and field action summary for theindustry).

Rooted in our commitment to patient safety, Glaukos’robust manufacturing processes, high level of Quality
oversight, and strong culture of continuous improvement
enabled the Company to again achieve no quality orsafety events requiring a product recall in 2023. We aim
to reach this goal again in 2024.

The Medical Safety team collaborates with the engineering department to evaluate the case and identify the root
cause during the complaint process. Once we identify theroot cause, the Quality team works with R&D to mitigate
future risks. Glaukos regularly reviews all complaints,monitors trends data, and analyzes the data for all
products on an ongoing basis.

One element that helps us achieve superior productquality and safety is robust training. Our annual target is
to aim for 100% of employees to complete Quality
Compliance and Patient Safety training. This goal
strengthens our commitment to product quality andpatient safety. All employees completed a quality andpatient safety training in 2023.

Zero product recalls
100% of employees complete Quality Compliance andPatient Safety training

Should a safety or quality event occur that could cause asignificant compliance or safety risk, our highly trained,cross-functional team would carefully assess the event's
potential compliance and safety risk. Per Glaukos' established procedures, we ensure prompt assessment andnotification to the appropriate government, regulatory,
and health authorities in those countries where there
could be an impact.

recalls for all markets in which we
distribute the product.
Glaukos will ensure the recalled product is tracked andreconciled against what was shipped to each impacted
customer when we perform a recall. Once all recall

28

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT INNOVATION
Pursuing new customer solutions through innovative, competitive product offerings by allocating resources to research and development, and strategically aligning acquisitions
with innovation and development needs
GRI 3-3; SASB HC-BP-000.B

P

roduct innovation is core to Glaukos’ mission totransform vision by pioneering novel, droplessplatform technologies that meaningfully advancethe standard of care and improve outcomes for patients
suffering from chronic eye diseases and disorders. If
Glaukos is not able to consistently innovate, we may
struggle to provide life-changing products and reduce ourability to compete in the marketplace.

Product innovation fuels Glaukos’ success and is determinative in achieving our goal to be a vision care leader.
Our internal and external stakeholders expect ourdevelopments to improve patient outcomes. From inception, Glaukos’ ethos has focused on innovation, seeking
to transform vision for patients suffering from chronic eyediseases. Continuing to innovate successfully will provide
a competitive advantage and create sustainable growth
opportunities, allowing us to further invest in our R&D

COMMITMENT TO INNOVATION

14

9
29

We are planning for a robust cadenceof new platform and productintroductions over the coming years
that have the potential toManagement Approach$500M

programs, clinical initiatives, people, systems, andinfrastructure to support long-term value creation andsuccess.

invested in research anddevelopment since 2018

disclosed pipeline products, including 11 pharmaceutical programs

currently commercialized products,
compared to one in 2012

fundamentally improve eye caretreatment options and transform
Glaukos over time.
Glaukos’ senior management is intimately involved withthe oversight of our product innovation process. Senior
management coordinates innovation efforts between our
R&D programs, clinical trials, and commercialization teams
through various quality, regulatory, operational, andpatient safety processes. Our R&D and Clinicaldepartments continuously track and monitor pipeline
program developments.
Our current projections for the commercialization of ourpipeline platform technologies forecast a cascade of new
product launches designed to significantly improve
patient care options. Collaboration with our key stakeholders, including eye care providers and patients, is an
important element of our product innovation process,including through continued input and feedback.
As of December 31, 2023, we had 14 active disclosed
pipeline programs across various R&D and clinical stages,
along with additional undisclosed programs (see table on
the following page). Of our 14 publicly disclosed pipeline

programs, 11 of them are primarily pharmaceutical (drug)
programs. The exact number of drugs in R&D isconfidential. We have two commercially available drugs.
Please see our filings with the U.S. Securities andExchange Commission for a more detailed discussion
regarding these products, accessible here . We arecontinuing to successfully invest in and advance ourfulsome pipeline of promising innovations of core novel
platforms, supported by over $500 million of self-funded
investment into our R&D programs since 2018.
Our thorough product innovation process includes aregularly updated product prioritization exercise todetermine which products we may pursue in the coming
years. This process involves evaluating risks andopportunities as well as patient needs.
When we begin introducing a new product, we assign a
project manager to guide the development of the productthrough the pipeline. The project manager is responsiblefor identifying and managing any challenges throughout
the product innovation process. These efforts have taken
Glaukos from a single commercialized product, the iStent,
in 2012 to nine in 2024, adding the iStent inject, iStent
inject W, iLink Epi-off, iPRIME, iAccess, iStent infinite,
Radius XR, and iDose TR.

iStent Micro-scale Surgical Devices
In August 2022, we announced FDA 510(k) clearance for
iStent infinite®, our novel three-stent injectable systemdesigned to provide foundational, 24/7 IOP control forglaucoma patients uncontrolled by prior medical andsurgical therapy.
The commercial availability for iStent infinite represents asignificant milestone for our company and the MIGS

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT INNOVATIONiSTENT INFINITE
We believe iStent infinite will spearhead our longheld mission to create a new Interventional
Glaucoma marketplace that seeks an alternative
treatment paradigm to advance patient care andhalt the progression of this chronic sightthreatening disease.

market as the first-ever micro-invasive implantable device indicated for use as astandalone glaucoma treatment. Over the course of 2023, we successfully advanced ourcommercial launch plans in the U.S. for iStent infinite. In the fourth quarter of 2023, we
commenced a PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients.

iLink Bio-activated Pharmaceuticals
During the second quarter of 2023, we completed enrollment in the second Phase 3
confirmatory trial for EpioxaTM, or Epi-on, our next-generation corneal cross-linking therapy
for the treatment of keratoconus.
This expeditious enrollment completion, which occurred in less than six months from trial
commencement in early 2023, is a testament to the favorable risk-benefit profile of thisnext-generation therapy as well as our team’s hard work in bringing this important raredisease therapy one step closer to patients suffering from keratoconus, a sight-threatening
corneal disease. We look forward to following these patients’ outcomes as we remain on
target for an NDA submission for Epioxa by the end of 2024.

iDOSE TR APPROVED

iDose Sustained-release Pharmaceuticals
In December 2023, we received U.S. FDA approval for iDose TR, our new, revolutionary,
micro-invasive, injectable treatment for the full range of glaucoma disease severity. iDose
TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy
designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of aglaucoma drug, travoprost, inside the eye for extended periods of time. iDose TR isintended to improve the standard of care by addressing the ubiquitous patient noncompliance issues and chronic side effects associated with topical glaucoma medications.
The response we have received from surgeons and the broader ophthalmic community
since we announced FDA approval for iDose TR has been overwhelmingly positive andreaffirms our view that with the launch of iDose TR, we are pioneering a brand-new
category of procedural pharmaceuticals that have the potential to reshape glaucoma
management as we know it today. We are excited to now be in the initial phases ofbringing this transformative technology to market and, in doing so, expanding thetreatment alternatives for patients suffering from glaucoma and ocular hypertension.
Looking ahead, we plan to commence a Phase 3 clinical program for iDose TREX, our next
generation iDose therapy, by the end of 2024.

30

iDose TR (above) compared to a single drop of IOP-lowering topical medication.

In December 2023, we received FDA approval of iDose TR, a micro-invasive,
injectable treatment for the full range of glaucoma disease severity. It is a first-of-its-kind intracameral procedural pharmaceutical designed to deliver 24/7
glaucoma drug therapy for up to three years. The FDA approval represents the
successful culmination of a 15-year development journey.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT INNOVATIONAs we continue to advance our clinical plans for Epioxa,
we remain well-positioned to serve keratoconus patientswith our first-generation CXL therapy, Photrexa, or Epi-off,which remains the only FDA-approved treatment shown toslow and halt the progression of keratoconus.

Retina XR

Over the course of 2023, we also continued to advancepatient enrollment in two Phase 2 trials for our thirdgeneration iLink therapy.

Progress Toward our Goals

iLution Transdermal Pharmaceuticals

FDA submissions of pipeline technologies that would
allow us to meet our publicly stated targets for FDA
approvals

In January 2023, we announced promising topline resultsfrom our Phase 2a first-in-human clinical trial for GLK-301
for the signs and symptoms of dry eye disease (DED) that
demonstrated improvement in the quality of tear film (tearbreak-up time) with corresponding improvement in qualityof vision (reduction in blurred vision). Based on theseencouraging observations, we plan to advance GLK-301
into a Phase 2b clinical trial in the future.
In the fourth quarter of 2023, we commenced a Phase 2aclinical trial for iLution Travoprost (GLK-311).

In the fourth quarter of 2023, we commenced a first-inhuman clinical trial for our retinal intravitreal multi-kinase
inhibitor (GLK-401) designed to treat wet AMD patients.

2023 Goals

Advancement of key clinical programs

Because our products undergo thorough review from the
FDA and other regulatory authorities and are subject toother factors outside our control, we may not be able tocontrol the timing of our product approvals. However, we
will endeavor to advance our products through the R&D

and clinical stages in a manner that would allow us tomeet our publicly stated FDA submission timelines.
Overall, we are pleased with our progress toward thesegoals based on the pipeline developments across our key
platform technologies as described above. Specifically, we
successfully received FDA approval for iDose TR in 2023,
consistent with our previously disclosed FDA approval
target. For Epi-on, we remain on track with our previously
disclosed FDA submission target by the end of 2024.
In terms of our earlier stage pipeline, we continue toprioritize the cadence of our R&D investments as we strive
to strike the right balance of risk-based spending and ourcapital position now and in the future. Notwithstanding
this stage-gated approach to R&D, we commenced
several new clinical trials in 2023, including (1) a PMA
pivotal trial for iStent infinite in mild-to-moderate glaucoma patients, (2) a Phase 2a clinical trial for iLution
Travoprost (GLK-311), and (3) a first-in-human clinical trial
for our retinal intravitreal multi-kinase inhibitor (GLK-401)
designed to treat wet AMD patients.

iDOSE TR CELEBRATIONTo recognize our company’s significant achievement insecuring FDA approval for iDose TR, we held a celebration party at our headquarters campus in Aliso Viejo, CA.
The widely attended celebration commemorated iDose
TR’s 15-year journey from original ideation to FDA approval and included toasts by various members of oursenior leadership team who played instrumental roles inthe development and regulatory success of iDose TR
over the past several decades.
In addition to an entertaining band and variety of foodtrucks, the event was capped off by a magnificent
Glaukos-themed drone show performance that lit up
the skies over our beautiful campus and may be viewed
here.
31

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXPRODUCT INNOVATIONSUMMARY OF CURRENTLY COMMERCIALIZED AND DISCLOSED PIPELINE PRODUCTS

32

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXACCESS, AFFORDABILITY, AND PRICING
Pricing products according to the value they deliver while employing flexible pricing approaches and support programs to ensure patient access
GRI 3-3; SASB HC-BP-240b.2

Glaukos believes that our mission, to createtransformative ophthalmic products that enrich
the lives of patients and provide innovative
treatment alternatives for those suffering from sightthreatening chronic eye diseases, encompasses a
responsibility to promote broad access to and thoughtfulconsideration of the affordability and pricing of our
products. We believe all individuals should have accessto affordable, high-quality care.

Without access to Glaukos’ glaucoma
and keratoconus treatments, certain
patients may be at risk for vision loss.
Failure to access adequate vision care can limit the qualityof an individual’s life, which is why we are committed toproviding broad access to our sight-saving therapies
through pricing based on value while creating meaningfulsupport programs for and donating our products toeconomically disadvantaged populations. As our business
continues to expand, so will our ability to profoundly
impact ophthalmic clinical outcomes and the quality ofour patients’ lives.

Management Approach
Our Access, Affordability, and Pricing programs areoverseen by the Global Marketing, Global Medical Affairs,
Market Access, and Patient Services organizations. We
carefully consider various factors when determining how
best to price our products, including patient total direct
medical costs and out-of-pocket costs, lifetime costsavings generated by our products, the potential
improvement of a patient’s quality of life, and the investment amount required to bring our products to market.
33

We also provide funding for research projects todetermine whether our products continue to represent
good value for patients. We regularly review the researchfindings examining the economics of the various ophthalmic care options and weigh the costs and efficacy of othertherapies against those of our own. For example, we
commissioned a study, published in the Journal of
Medical Economics1, that compared the cumulative costof a two-stent glaucoma treatment using our iStent technologies with that of alternative glaucoma treatments suchas laser trabeculoplasty or medications only.
The study found that over five years, the cost of ourinnovative iStent technologies is lower than that of thealternative glaucoma treatments. Studies such as thisdemonstrate the value created and relative affordability of

our iStent technologies for both our patients and thehealthcare system.

Similarly, in connection with the 2020 price increase of ouriLink therapies to treat a corneal health rare disease called
keratoconus, we evaluated the value our iLink technology
provides to both an individual keratoconus patient as wellas the broader healthcare system. For example, a Glaukos
supported 2020 study published in the Journal of Medical
Economics2 modeled the cost-effectiveness of crosslinking (CXL) with iLink versus no CXL for 2,000 U.S.
keratoconus patients (4,000 eyes). The findings included:• The CXL group was 25.9% less likely to undergo pene-

trating keratoplasty (corneal transplantation) and spent
27.9 fewer years in advanced disease stages.

HELPING PATIENTS RECEIVE SIGHT-PRESERVING TREATMENT“A determined and worried mother reached out for help with her son
after he was diagnosed with keratoconus,” explained Elly Nguyen, Sr.
Patient Support Specialist, pictured here. “They were advised by theirophthalmologist that the disease was progressing but the iLink
treatment was not covered by their insurance. The patient’s mothercontacted Glaukos Patient Services for support. Through the Patient
Assistance Program, the Photrexa drug was donated by Glaukos, andthis young man was able to be treated.
“The mother has shared with us her gratitude for the program and therelief that her son’s keratoconus has stopped and that his vision could
be corrected to see again. Since being treated he is back to excellingin school and sports – and just being a kid now that progressive
keratoconus has been halted! We look forward to helping thiswonderful family again with the program as they prepare for theirson’s second eye to be treated soon.”
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXACCESS, AFFORDABILITY, AND PRICING• CXL had lower total direct medical costs ($30,994 vs. $39,671, a savings of $8,677 or

iDOSE YOUR DOSE PROGRAM

22%).
• CXL was associated with lifetime cost-savings of $43,759 per patient. CXL was cost-effective within 2 years and cost-saving within 4.5 years.
• Patient quality of life was improved in the CXL group. CXL was associated with a 9%

improvement (gain of 1.88 quality adjusted life years) compared to no CXL over thepatient’s lifetime.
Based on these findings and similar internal evaluations, we modestly increased the list
price of the drug used in our U.S. iLink product, Photrexa, over the last several years (~8%annual average since 2019, the year we acquired Avedro). Based upon the investment
made to bring this orphan drug to market, the continued efforts to expand access topatients with this rare disease, and the researched economics described above, we
believe that our pricing strategies are well-supported and will benefit patients.
We provide written communications regarding price increases to customers and relevant
insurance payors, emphasizing the significant investments we continue to make to broaden patient awareness and access to our iLink therapy and to develop next generation CXLtechnologies designed to provide less invasive treatment options.
At the end of 2023, we received U.S. FDA approval for iDose TR, our new, revolutionary,
micro-invasive, injectable treatment for the full range of glaucoma disease severity
product. iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary
formulation of a glaucoma drug, travoprost, inside the eye for extended periods of time.
iDose TR is intended to improve the standard of care by addressing the ubiquitous patient
non-compliance issues and chronic side effects associated with topical glaucoma
medications.

We believe iDose TR offers a compelling value to patients. Various factors, including arobust set of internal pharmacoeconomic analyses, helped support our initial pricing
strategy for iDose TR, which also reflects the significant investments we have made to develop and make a new game-changing therapy for glaucoma patients. We believe iDose
TR provides a strong value proposition for physicians and payers as one of the mostcost-effective procedural pharmaceuticals in ophthalmology when annualized based on
its design to deliver up to 3 years of drug therapy.
With the launch of iDose TR, we recognize a responsibility to support broad patient
access. To support this critical focus of ours, we have invested more resources in ourrobust patient services team, known as Glaukos Patient Services (discussed further below),that is designed to help support patients and their providers through their treatment
34

Glaukos is committed to ensuring that every
eligible patient who may benefit from iDose
TR will have access regardless of insurance
coverage restrictions or the patients’ ability
to pay. As such, we have built an allencompassing, comprehensive patientadvocacy and access program to support
this goal. As part of this, Glaukos is proud
to highlight the iDose Your Dose philanthropic initiative. For every iDose TR
sold, Glaukos pledges to make available an equal number of iDose TR units for
qualifying charitable donation requests in the U.S. and around the globe forrecipients that satisfy independent eligibility requirements.
journey by providing a system inclusive of patient education, insurance counseling,financial co-pay assistance for eligible patients, and comprehensive market accesssupport, including billing and coding assistance. We will also have Specialty Pharmacy
options available for our customers.
For certain products, we offer discounts and /or rebates to customers based on volume orother metrics and have pricing schemes that differ depending upon the site of service andthe reimbursement environment in a particular geography. Our pricing terms are
considered confidential information, and our customers agree contractually to maintainsuch confidentiality. Lastly, we educate optometrists on keratoconus and partner with theleading patient advocacy organization, National Keratoconus Foundation, to help improve
patient awareness.
Additionally, Glaukos has reinvested more than 30% of global sales into research anddevelopment activities over the last five years to relentlessly advance the treatment of
ophthalmic diseases and disorders. Furthermore, given the significant lifetime cost-savings
per patient and the broad reimbursement available for our products, we are confident that
Glaukos’ therapies represent valuable treatment.

Patient Services
Glaukos Patient Services (GPS) began in 2022 as an initiative designed to help patients innavigating the journey from suspicion of having keratoconus to diagnosis and treatment.
GPS works with patients, their legal guardians, and eye care providers to provide highGlaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXACCESS, AFFORDABILITY, AND PRICING
quality patient education to explain the importance of early detection and intervention.
GPS also helps patients understand their individual insurance benefits and inform thepatient of financial assistance offerings for which they may qualify, which at times can bechallenging given the rare nature of the disease. Importantly, it helps patients avoid
treatment delays that may result in worsening keratoconus, as well as unnecessary financial
burdens to patients.
The positive reaction from both the patient and healthcare provider community has
confirmed our belief that we are making a difference for patients afflicted with keratoconus. In response, Glaukos continued to invest in people and infrastructure to grow the
program and expand our offerings. Throughout 2023, GPS expanded across the country
and served over 3,000 keratoconus patients in their unique journey to crosslinking
treatment. GPS faced the challenge of attracting and hiring people with the right fit for
Glaukos and brought in a full team of patient-centric individuals who tirelessly work to findavenues to access and treatment.

GPS has led the Glaukos organization to a deeper understanding of the complexities thatpatients with sight-threatening diseases face and expects to further expand its efforts in
2024.

Access, Volunteerism, and Charitable Giving
In the United States, Glaukos is committed to providing patients access to our glaucoma
and corneal health technologies by:• Ensuring that payers understand the social and economic value of preserving sight andincluding Glaukos’ treatments in their members’ benefits;• Collaborating with patient advocacy organizations to educate and empower theirmembers to seek and receive sight-preserving treatment options;• Helping patients understand their diagnosis and assist with navigating their treatment

journey, including connecting them with patient advocacy organizations;• Offering a Patient Savings Program (PSP) to assist commercially insured patients withSUPPORTING ADVOCACY GROUPS
Because individuals with Down syndrome have a higher risk of developing keratoconus, Glaukos partners
with the National Down Syndrome Society to raiseawareness and encourage early diagnosis andtreatment. In addition to supporting the nearly 2,000
walkers at their annual New York City Buddy Walk forthe second year, Glaukos also sponsored the National
Down Syndrome Societies’ (NDSS) 2023 Adult Summit
in Cincinnati, Ohio.
The NDSS Adult Summit
was an interactive conference that discussed the topic of aging and Down
syndrome through a whole-person, comprehensive
approach addressing the needs of teens and adults
with Down syndrome by providing practicalresources, materials, and educational and vendor
opportunities for individuals, families, caregivers,
and professionals.
35

their out-of-pocket cost burden; and• Providing donated products through programs like our Patient Assistance Program(PAP) for qualifying under-insured and uninsured patients who fall below 400% of theFederal poverty income level.
Internationally, Glaukos is committed to providing access to our technologies by:• Donating devices to surgeons doing surgical missions in a cumulative total of 53

different countries in collaboration with 134 cumulative charity organizations in orderto help underserved glaucoma patients;• Fostering and expanding a robust network of ophthalmologists who do surgicalmissions and, where applicable, connecting them with local international resources; and• Establishing surgical training opportunities for untrained surgeons in internationalcountries who often become the first MIGS surgeons in previously unreached countries
and regions.
In addition, Glaukos increased distribution of our Photrexa drug kits though specialty
pharmacy channels in 2023 which streamlined use of the PSP. Those changes resulted ineasier access to the PSP which provided some patients with a zero out-of-pocket costburden for this product. Glaukos also partners with high-risk glaucoma patient groups toprovide support and raise awareness. For example, in March 2023, Glaukos provided
iStent devices, iStent eye models, and training supplies to a glaucoma surgery training
program in Indonesia. This program is summarized on the following page.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXACCESS, AFFORDABILITY, AND PRICING
Glaukos Charitable Foundation
The Glaukos Charitable Foundation (Glaukos Foundation),
a qualified 501c (3) tax-exempt organization, supports ourcharitable endeavors. The Foundation’s mission is tosupport charitable organizations and programs designed
to improve the well-being of humanity worldwide. It
administers Glaukos’ philanthropic activities and creates asystematic and efficient process to distribute philanthropic
dollars, aligned with our mission. Through various outreach programs, the Glaukos Foundation also connects
Glaukos employees with opportunities to volunteer orcontribute to the improvement of the lives of others.
Further, volunteerism and charitable giving are
inextricably tied to our Company culture and an emphasison the accessibility of our products. One of the main
components of Glaukos’ ethos is giving back. Company
employees receive 16 hours of paid Volunteer Time Off(VTO) annually to encourage giving back to the communities that we serve. Additionally, employees can donate
their Paid Time Off (PTO) to a general PTO bank that we
use to assist employees in need but who may not have
PTO available to use. As of December 31, 2023, over
3,100 hours of PTO have been donated and over 600 of
those donated hours have been distributed to employees
who were seriously ill or injured or experienced hardship,including the loss of a loved one, since we introduced theprogram in 2017. This program allows us to support eachother in times of need.

Progress Toward our Goals

Glaukos has established a culture of giving through our
PAP. In 2023, Glaukos provided more than 2,500 Photrexa
kits to uninsured or underinsured individuals for thetreatment of keratoconus.
In conjunction with the launch of GPS in the U.S., we wereable to increase our direct communications with patients
about available assistance programs, serving over 3,000
keratoconus patients in 2023. In 2023, we also donatedmore than 640 stents and 400 gonioprisms to benefit
underserved glaucoma patients across the globe. To date,
we have partnered with 134 cumulative humanitarianorganizations in 53 different countries, supplying Glaukos
products to enable sight-saving surgeries for patients whootherwise would not have access to such care.

•

By 2025, provide a comprehensive range of services
to U.S. patients and caregivers enrolled through ahealthcare provider or self-enrolled to support thecritical phase of early decision-making about theirkeratoconus or glaucoma care;•

By 2027, develop a team of Patient Ambassadors to
educate U.S. patient and advocacy organizations and•By 2030, surpass 10,000 cumulative stent donations
and 150 recipient organizations.

Through outreach to ophthalmological charity organizations independently and at academic conferences, as wellas individual meetings with physicians affiliated withmission trips, we were able to organically grow thenumber of countries served and partnerships withhumanitarian organizations. We also increased ourinternal and external communications to better educate
employees and the public on the availability of thesephilanthropic efforts.
Our overall goal with respect to Access, Affordability, andPricing is to continue to support multiple assistanceprograms by providing products to support underserved
patient populations as well as to donate our employees’
time and Company resources to institutions that focus on
the betterment of humanity. To that end, we haveestablished several goals for the future including:2023 Goals•

Increase number of patients who receive assistance fromone of Glaukos’ assistance programs

In 2024, help >5000 patients navigate theirkeratoconus treatment journey;•

To ensure that our sight-preserving products areaccessible to patients from underserved populations,

Establish processes to make iDose accessible tounderserved communities via the iDose Your Dose
global program;•

In coordination with patient advocacy organizations,36

support patients with educational materials to build
awareness of early intervention, find community, andmanage their disease;

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXACCESS, AFFORDABILITY, AND PRICINGPROVIDING ASSISTANCE IN UNDERSERVED REGI ONS OF THE WORLDThe Glaukos Foundation helps to preserve vision for individuals in underserved regions
around the world through donation of our products to humanitarian organizations. Two
examples are highlighted below.

MIGS Training in Indonesia
In March 2023, The Cure Glaucoma Foundation, in collaboration with The Glaucoma
Society of Indonesia and Udayana University/Mangusada Hospital, successfully concluded
the MIGS Didactic Course and Wet Labs Conference in Bali, Indonesia. This educational
initiative focused on training 36 Indonesian surgeons in various glaucoma procedures,with an emphasis on the MIGS procedure. During the three-day event, 22 surgeries were
performed. Glaukos was proud to donate 45 iStent devices, 30 iStent eye models andother training supplies to this program.
Conference organizers are hopeful that it will have a lasting impact
on glaucoma management in Indonesia as the expertise and experience acquired by these surgeons
will inspire others to explore andadopt innovative procedures.
Dr. Tosin Smith, one of the conference organizers, commented on
the program's far-reaching effects,
Indonesian clinicians give a “thumbs up” to their Marchstating, "The joy of organizing and2023 MIGS training program supported by Glaukos.
delivering this program lies in
witnessing the ripple effect it has on physician education and patient care in Indonesia
and other countries worldwide. The impact of the program is not only to treat thosepatients that we see, but to bring those surgeons up to date and provide them with follow
up as they get comfortable with these newer glaucoma treatment procedures.”supported by Glaukos in November 2023. These
teams consist of ophthalmic surgeons, nurses,
optometrists, and staff who volunteer their time,
talents, and money to provide quality eye care to
Guatemalans who otherwise have little or no accessto care.
The teams see approximately 1,000 patients andperform approximately 150 surgeries annually,
amounting to over $300,000 worth of donatedmedical and surgical care. The majority of surgeries
are sight-restoring and often life-changing cataract
surgeries and/or glaucoma procedures. In addition, the IEI teams support two local Guatemalan
doctors who provide a surgical training program forone surgical Fellow each year. This year, the Fellow
The IEI team prepares to treat a 7 year-old
will return to his home in El Salvador as one of only
patient with bilateral congenital cataracts
and 20/100 vision.
two surgeons trained in modern eye surgery in thethird-largest city in his country. In the words ofDr. Dance, “we are so proud to have invested in
the development of an expert eye surgeon who
will be such a gift to El Salvador […] Partneringwith the local doctors and Fellow has allowed us
to greatly expand the quality and reach of oursurgical mission trips.”

Guatemala Mission Trip
The International Eye Institute, Inc. (IEI) is a private non-profit 501(c)(3) organization thatprovides medical and surgical eye care to people with little to no access to these services.
Their primary focus is to develop and strengthen partnerships with hospitals andcommunities in Guatemala, Honduras, Peru, and Nicaragua. Each year, IEI sends at least
two teams to Santiago Atitlan, Guatemala, such as the team led by Dr. David Dance and
37

The IEI team completed 89 surgeries during
the week-long mission supported by Glaukos
product donations.

Dr. Dance added, “There is great joy in seeing ablind person regain their sight. This is madepossible by our volunteers and support from ourindustry partners, corporations, foundations, andmany kindhearted donors. Our teams really dotransform the lives of these patients and impact
each of their families in a profoundly beneficial
way. We, and THEY, are grateful for your generous
support. Indeed, when the patch is removed andour patients re-experience sight, they express
genuine and unrestrained gratitude which wewish to pass on to you!”
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXSOCIALAt the heart of our success is the belief that ouremployees are not just contributors but thesource driving our innovation and growth. We

are committed to making Glaukos an engaging,diverse, and safe place to work.

GOALS SET IN 2023

TALENT ATTRACTION,
DEVELOPMENT,ENGAGEMENT, AND
RETENTIONGOALS SET IN 2024

Based on this year’s Great Place to Work engagement survey
results, identify areas of opportunity; communicate andmeasure progress against improvement areas in the following
year

Based on this year’s Great Place to Work engagement survey results,
identify areas of opportunity; communicate and measure progressagainst improvement areas in the following year

Expand leadership and employee development for targeted
employee groups with the addition of at least three new programs; report employee hours of training globally and learning
outcomes for applicable programs by 2024

Continue the strategic expansion of leadership and employee
development activities with pilot launch of at least three leadershipand employee development activities

DIVERSITY AND
INCLUSIONAs led by our DEI Forum, identify and implement at least twocompany-wide initiatives and success measures that will expand
Glaukos’ approach to diversity, equity, and inclusion by 2024

WORKFORCE HEALTHAND SAFETY

Conduct an annual Health and Safety risk assessment andimplement at least one new initiative annually to mitigate the
top risk identified38

YE 2023
STATUSAs led by our DEI Forum, continue to expand Glaukos’ approach todiversity, equity, and inclusion

Develop strategic and intentional recruitment outreach efforts todiverse candidates
Conduct an annual Health and Safety risk assessment andimplement at least one new initiative annually to mitigate the top risk
identified
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION
Developing and implementing global strategies for attracting, developing, engaging, and retaining workers, including offering market-competitive compensation, bonuses,
benefits, and equity at all levels in the Company for eligible employees, providing career path opportunities and promoting employee satisfaction
GRI 3-3; GRI 401-1; GRI 401-3; GRI 403-6; GRI 404-2; GRI 404-3

Glaukos’ success depends on the attraction,
development, engagement, and retention of talented individuals in the global markets where wecompete. We foster a culture of diverse and engaged
people, and we promote an inclusive and collaborativeenvironment that is critical to achieving our strategic planand business success.

Management Approach
Glaukos is a rapidly growing company. Creating andmaintaining a positive workplace culture is vital to attracting and retaining talented employees. Our ability to execute our strategic vision depends upon the talented individuals we employ. Glaukos seeks to create an experience that enables our employees to focus on our sharedgoal of improving the lives of patients and developing

TALENT ECOSYSTEM

39transformative technologies. For more information on ourefforts to create a comprehensive, cohesive, and positive
employee experience, please see our 2023 Form 10-K.

PEOPLE/TALENT WHEEL

Glaukos uses two frameworks to influence and advanceour talent strategies and actions. The first model, which
we refer to as the People/Talent Wheel, considers how
business strategy impacts five people-related approaches:
Talent Acquisition, Onboarding, Development, Engagement, and Retention. The second model, the Talent Ecosystem, collects information on our quarterly Career andPerformance Check-Ins. The Talent Ecosystem helps leaders represent employees at Talent Calibration meetings,
influences how we identify successors and prepares themfor future roles.
In 2022, Glaukos developed and implemented a People
and Talent Strategy to support and directly align with ourbusiness strategy. Each focus area helps prioritize supporting programs, resources, and leadership to provide
an exceptional employee experience where people want
to work, grow, and stay. The People and Talent strategy isshared in senior team meetings and in leadership development programs to educate leaders on their range ofroles in finding, developing, and engaging people. In
2022, we also designed our Job Leveling Framework,
which was implemented in 2023. This process uses a
standard set of criteria to consistently assign job titles andlevels and calibrate each job in the company. The guidecontains detailed criteria for each level in our frameworkand is used as a guidepost to provide managers and employees with criteria to create a pathway towards development and promotion.

In 2023, we used this guide to apply consistent criteria
globally across the organization. During 2023, leaders
continued to develop their skill in applying the levelingguides within their functions with some functions tailoringleveling guides with function-specific nomenclature forresponsibilities, skills, experience, and leadership criteria.
We use the job leveling guide to level new jobs in theorganization and to ensure accuracy of job descriptions.
We continue to expand these guides by department,
where needed, to provide a framework for employees tosupport career progression for their specific function andpromote equity and consistency when making promotion
and hiring decisions. This process supports many Glaukos
values and business objectives, including career development and competitive compensation, and helps maintaina high caliber of talent at each level. Job Leveling is expected to support improved employee engagement, satisfaction, retention, equity, and overall productivity.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION
We continue to offer our signature leadership development program, Leader Lab. Leader Lab content includes
in-person and virtual training and the use of EQi
leadership assessment that aligns with the Glaukos Values
and Leadership Behaviors. Since its inception in 2021, 86
leaders have completed Leader Lab, and 25 leadersparticipated in 2023.
Our senior leaders review people, talent statistics, andprograms with our Board of Directors at least twice per
year. Members of management participate in shareholder
outreach calls and meet with some of our top institutional
investors. As part of these calls, management provides
updates on how Glaukos supports our organization
through hiring, development, compensation, andengagement practices. Additionally, we conduct an annual Great Place to Work survey that provides rich qualitativeand quantitative data and has influenced several changes
and additions to benefits, training, and workplaceamenities.

The Glaukos Culture
The Glaukos Values — Dream, Lead, and Care — describeand embody the spirit and behaviors uniquely critical to
Glaukos. Our Values are incorporated and referenced
throughout the Talent cycle, from recruiting to onboarding to engagement and retention. Our DARE Awards
recognize Glaukos employees whose actions, behaviors,
and achievements exemplify Dream, Lead, and Care.
Sponsored by CEO Tom Burns, the Senior Leadership
Team reviews and approves award winners. In 2023, 44
employees were nominated, and 10 employees wereawarded DARE recognition and cash bonuses.
Glaukos values employee feedback, so for the third year
in a row, Glaukos participated in the Great Place to Work
employee survey. 83% of our employees completed thesurvey. 89% of the respondents said Glaukos is a greatplace to work compared to 57% of employees at a typical
U.S.-based company. Based on the survey results, our top

EMPLOYEE STATISTICS
Total:

By Geography:

By Age:DARE AWARDS
Sr. Scientist II William Tran was
nominated for a DARE award for
his leadership of an R&D project,moving from ideation to a feasible
device. Will accomplished thisthrough creative resourcing, cross-team partnership, and personal dedication, including traveling internationally to train global
clinical leaders and support study development
and monitoring.
strengths include the categories of Corporate Intimacy
and Caring, with especially high results on pride inworking at Glaukos and recommending it as a place forothers to work, feeling good about the ways wecontribute to the community, and customers rating ourservice as “excellent.”

In addition to the U.S., Australia washonored as a Great Place to Work forthe third consecutive year. Brazil,
France, Germany, Japan, and the
U.K. also garnered Great Place toWork designations. Additionally, forthe second consecutive year,
Glaukos was named Fortune Best
Workplace in Biopharma.

40

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTIONEVENTS AND TRADITIONS

Employees embrace 2023’s blockbuster Barbie as part of the company’s annual Halloween costume contest.

The Glaukos culture is defined and shaped insmall but historically important ways throughcontests, games, and recognition like Halloween
costume contests, Friday Food Trucks at the U.S.
offices, holiday decorating, a day off on Glaukos
Day, and Blueboard awards for milestone service
anniversaries. Employees regularly cite these
special, fun events as part of what attracts andkeeps them at Glaukos.

As in previous years, Glaukos took immediate action on
the 2023 survey results, focusing on communication andcollaboration. As the company progresses in its growthand expansion, additional learning and development
programs and leadership actions are in place to help
teams and organizations work even more effectively. The
design and implementation of a new SharePoint Intranet
41

began in April 2023 and launched in January 2024. As acomplement to our cross-functional, companywide Major
Business Objective process that drives support of business imperatives, we also revamped All Hands Meetings
to include more interactive sessions and company
knowledge sharing. From a career and development perspective, the “Grow Your Development” class was implemented to help employees and people leaders navigate
promotion and development. Three additional learningand development classes were designed and implemented, and we launched Glaukos World Café to promotelearning and exploration of Diversity, Equity, and Inclusion
topics relevant to all employees.

Employee Wellness, Benefits, and Compensation
Glaukos recognizes that our 900+ employees have a wide
range of needs and wants related to benefits andwellness; therefore, we regularly review, modify, and add
a suite of competitive employee wellness, benefits, andcompensation approaches. Our Global Total Rewards
approach is vital in attracting, developing, and retaininga healthy and satisfied workforce.
Compensation. We apply the following principles to help
achieve consistent, fair compensation packages thatreward performance:• Base salaries, discretionary bonuses, and benefits

packages are based on, competitive in, and appropriate
for, each of the markets where we compete for talent.
• Individual performance with a balance of short and long-term objectives.
• Compensation that encourages behaviors that areconsistent with our values.

SCIENCE FAIRIn December 2023, the Glaukos R&D functions presented a Science Fairto the Board of Directors and employees at the Aliso Viejo, California
headquarters. Glaukos scientists and engineers prepared posters andinteractive product demonstrations to bring our robust pipeline to life.
Employees and board members had fun exploring the product andformulation development processes, the mechanics behind the operationof various devices and testing new products, with guidance and insightfrom the scientists and engineers who had helped develop them.
Employees shared that interacting with the products increased theirconnection to our science and our mission. The presenters worked hardon their presentations and took pride in doing so, and it showed! Futurescience fairs are planned for 2024 for the commercial and manufacturing
teams, as well as external collaborators, and beyond.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION• Processes to ensure consistency in compensation acrosssimilar roles in relevant markets regardless of race,
ethnicity, or gender. Please visit the Diversity andInclusion section of this report to learn more about ourcommitment to pay equity.
Glaukos executive compensation programs are designed
to attract and retain high-caliber executives. The executive
compensation programs link the executive management
team to shareholder interests. Glaukos executives receive
base salaries and employee benefits that are market
competitive. A significant portion of the annual compensation for our executive leadership team is based on the
Company’s annual business performance, including
achievement of our sustainability goals, and each
executive’s contribution to that performance. The
executive compensation programs reward our executive
leadership for achieving short- and long-term results. For
more information about our executive compensation
program, please see our most recent Proxy Statement.

Another key component of our totalcompensation approach is to enable
employees to build an ownershipstake in our Company.
We operate with several programs to enable ownership in
the Company:• Glaukos’ long-term incentive program grants restricted

stock units (RSUs) to eligible employees. Over time,
when the awards vest, they are paid out in shares of
Glaukos common stock (country-specific exceptions
may apply). In the United States, employees at every
level within the organization receive a new hire grant
upon hiring and are eligible for additional RSUs during
42

our annual performance-based compensation review.
• Glaukos offers employees the opportunity to purchase

Glaukos stock at a discount through the Employee
Stock Purchase Plan (ESPP). The ESPP is available to any
employee or personnel hired through a professional
employer organization worldwide who customarily
works at least 20 hours per week. As of December 2023,
62% of eligible personnel participated in the ESPP
program.
Wellness and Benefits. Glaukos takes a holistic approachto employee well-being tailored to each market in which
we have employees. We offer programs that support awork-life balance and promote good health and mental
well-being. Glaukos offers an Employee Assistance
Program (EAP) to all global employees and their family
members. EAP provides health and wellness resources,
including:• Counseling services for emotional care.

PARENTAL LEAVE
We are proud that ourparental leave benefit
remains accessible to all
regular, full-time and parttime employees globally,
with no minimum eligibility
requirement.

• Ways to manage stress and anxiety during uncertainty.
• Financial and legal planning resources.

• Local resources, including where to find childcare andelder care.
In the United States, we offer a wellness reimbursement
credit to our employees, allowing them to be reimbursed
for eligible expenses spanning physical, financial, andmental wellness.
We review our global programs periodically to ensurecompetitiveness within our industry. International
employee eligibility for non-salary benefits follows local
regulations and practices. We offer the following benefits
in the U.S.:• Healthcare Benefits that are designed to support thewellness of our employees. Benefits include medical,
dental, and vision insurance, a Health Savings Account(HSA) with an employer contribution, limited purpose
flexible spending accounts, and access to virtual healthservices. Glaukos pays 100% of vision insurance in the
U.S. and provides a second pair of glasses or contactlenses annually.
• Insurance Benefits to ensure that those who rely on

Glaukos employees for support can help protect theirfamily’s financial security. Benefits include Companypaid Life/AD&D and long-term disability, paid shortterm disability, voluntary supplemental life, critical
illness, and hospital indemnity insurance.
• Retirement Benefits to allow employees a tax-

advantaged way to save money to achieve their retirement goals. Glaukos offers a 50% match of the first 6%of annual eligible compensation that employees
contribute.
In addition to our Wellness Reimbursement Account,
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION
other wellness initiatives include onsite COVID-19 and flu
shots for 179 employees in our U.S. offices, biometricscreenings, and Wellness Wednesday massage therapy at
our locations in Aliso Viejo, CA, San Clemente, CA, andBurlington, MA.
As we continue to expand globally, Glaukos regularly reviews and enhances our benefits to be a competitive employer. In 2022, we improved pension benefits in the U.K.,
launched pension benefits in Germany and France, andintroduced supplemental health insurance in the U.K. andFrance. In 2023, we enhanced Canadian benefit competitiveness and reviewed all other countries for competitiveness based on their respective markets. Depending on
their role and the country in which they work, employees
worldwide have access to flexible and hybrid work options.
Globally, we offer Time Off Programs that allow employees to refresh and spend time in the community
volunteering, paid Company holidays, Company-paidbereavement, maternity and parental leave, and Company-paid Leaves of Absence for employees and theirdependents with qualifying disabilities.

Effective January 1, 2024, all U.S.
exempt employees became eligible toparticipate in Trackless Time Off,which is paid time off without accruingor depleting a balance. The change
reduces administration for employees
and people leaders, and offers
increased flexibility and choice.
43

Inspired by feedback from the Great Place to Work survey,
Glaukos offers a global shutdown the week of December
25-29. This shutdown does not require employees in mostcountries to use PTO. Feedback from this initiative has
been positive. Some employees in certain functions wererequired to work during the shutdown and were issued
equivalent holiday credits to be used at another time.

example, the Talent Acquisition team attended oncampus recruiting events with the goal of attracting
candidates for our internship program, which continues toserve as a pipeline to fill some of our R&D positions.

LEADERSHIP TRAINING

Glaukos supplements disability insurance proceeds, PTO,
and leave-related payments to provide up to 12 weeks ofpaid disability, maternity, and baby bonding for allparents. Employees returning from qualified paid leave of
up to 12 weeks are given full merit, bonus, and equity
consideration and will not have their compensation
impacted. In addition, we offer two weeks of parental
leave for baby bonding for a non-birthing parent, which
includes state-registered domestic partners.

Employee Attraction
Glaukos’ unique culture, product pipeline, and everexpanding benefits to attract the best people make us an
attractive place for employees. The competition for skilled
talent remains high, and our employee value proposition
allows Glaukos to compete successfully against muchlarger medical device and pharmaceutical companies.
Our Talent Acquisition team collaborates with businessleaders and hiring managers to develop talent pipelines,
candidate pools, and interviewing approaches. In
partnership with Learning and Development, we
introduced “Source and Select”—a complete class forhiring managers to learn and apply more sophisticatedmethods of preparing for hiring, conducting interviews,
and onboarding new hires. Since innovation is key to our
success, we continue to pay close attention to our talent
and attraction practices for our science and R&D roles. For

Glaukos’ signature leadership development programs, Leader Lab and Launch, continued in 2023.
Leader Lab was offered to three cohorts ofexperienced managers through senior directors tostrengthen their ability to effectively facilitate performance, career, and development discussions. In
Leader Lab, leaders learn, practice, and apply
facilitative coaching and two models for giving andreceiving feedback.
Launch was redesigned in 2023 and offered tothree cohorts of leaders new to management.
Launch offers both basic leadership development
skills and management skills related to employee
relations and legal requirements.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTIONDARE TO CARE: PROMOTING A CULTURE OF GIVING AND VOLUNTEERISM
Care, one of three Glaukos core values, was on full
display in 2023. We sponsored 21 volunteer
events with seven different nonprofit organizations
and logged over 650 volunteer hours. In addition,
employees around the world adopted 194 families, providing various goods, services, food, andholiday gifts in conjunction with organizations like
Beyond Blindness, Families Forward, Variety-The
Children’s Charity, and Action for Boston’sCommunity Development.
We implemented the first Glaukos “Dare to Care”
event in October and employees donated money,
clothing, and goods for Friends of Boston’sHomeless, Operation Gratitude (supplies forsoldiers in combat), Working Wardrobes (grocery
and gas gift cards and donated business attire),
University of California Irvine (UCI), and the UCI
Anti-Cancer Challenge bike rides and walks,
Serra’s Pantry, Someone Cares Soup Kitchen, Beyond Blindness Golf Fundraiser, and Burlington
Lawn Mowers Dream Team.

EUROPE

U.S., CANADA, AND
SOUTH AMERICAJAPAN

AUSTRALIA / NEW ZEALAND

Employees also donated 415 pairs of eyeglasses
to Lions in Sight, donated blood at four Red Cross
Blood Drives in Southern California, packaged
37,162 meals at the 2023 Global Sales Meeting,and raised $68,340 at our annual Thanksgiving
Fundraising Campaign for the Orange County
Food Bank and the Greater Boston Food Bank.
44

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION
In addition, the talent acquisition team worked with our business leaders to create talentpipelines for roles critical to our business. It is important to Glaukos to focus on developing as diverse slates of candidates as possible. We continue to partner with a veteran’sorganization that helps match veterans with employers. In 2023, some of our internal Veterans attended job fairs for local veterans in partnership with our Talent Acquisition team,which resulted in the hire of a local veteran in our Operations organization. Our job postings and outreach efforts include diversity- and minority-focused groups and organizations, veterans, and women-focused groups and associations. In preparing our job
postings, we use a gender decoder to ensure that we use neutral verbiage. Further, uponreceiving a new requisition, our Recruiters highlight the importance of diversity with ourHiring Managers as part of our regular practice before beginning a new search.

In 2023, new employees were invited to attend virtual andin-person “Glaukos Product and Disease State Training, ” aclass that provides all employees with useful information
on Glaukos’ unique products. Feedback on this class wasvery positive—overall satisfaction was 95%.
We also utilize social media to reach younger generations of talent. Our social media
strategy highlights Glaukos’ culture. Some of our shared stories include Glaucoma
Awareness Month; Global Health & Fitness Month; Holiday Shutdown the week between
Christmas and New Year’s Eve; National Working Parents Day; Glaukos Holiday parties;
Employee volunteerism; World Keratoconus Day; Great Place to Work and Best Workplace in Biopharma recognitions.

Employee Growth, Development, and Retention

SKILLS BRIDGE PROGRAM
Knowing that talented people are in all walks oflife, Glaukos partners with Skill Bridge, a program
sponsored by the Department of Defense (DOD)
in which service members gain valuable civilian
work experience through specific industry training,
apprenticeships, or internships during their last
180 days of service. DOD Skill Bridge connects
transitioning service members with industry partners in real-world job experiences.
With support from Glaukos employees Jennifer
Ringdahl, Manager, Talent Acquisition, and Chris
Damyen, Facilities Manager and former Gunnery
Sergeant, former Motor Transport Operations
Chief Jacob Mackenzie joined Glaukos as a Facilities Technician in charge of
office, clean room and HVAC equipment and facilities maintenance at our Aliso
Viejo campus.
“Leading up to the starting day of the Skill Bridge program, I was nervous andexcited at the same time because I didn’t know what to expect,” said Jacob, pictured above. “I was transitioning out of what I’ve known and done for the past 12
years and into a new role. Even after five months, I find the environment at Glaukos is extraordinary. I couldn’t have imagined such a warm welcome and somuch overall support.”

We work to provide employees with the skills and tools needed to reach their careergoals. Formal learning and development are available in functional and technical areas
such as Clinical, Commercial, and Quality. iLearn, our global Learning Management System, is available in seven languages and offers over 16,000 learning activities for employees to enhance their skills.

development across activities and programs in various business, financial, technical, interpersonal, and leadership topics. This represents nearly two times more documented training than in 2022. Over a thousand hours of Good Practices Quality and Compliance training were completed by employees, temporaries, and contractors.

In 2023, Glaukos employees engaged in over 6,000 hours of documented learning andResearch indicates that the quality of orientation and longer-term onboarding has

45

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTIONJUST-IN-TIME DEVELOPMENT

A visible example of cross-function collaborationand teamwork was the design, development, andimplementation of “PAI Readiness” training. The
class was created in collaboration with Manufacturing Operations leaders and Learning and Development. Using a competitive game backdrop,
participants learned and applied communication
skills to effectively interact with external FDA
auditors on site. Over 130 participants completed
the class, and the results were positive: 54% ofparticipants said that before the class, they felt
prepared to interact with auditors; after the class,
96% said they felt prepared or very prepared.

significant, positive impacts on employee engagement,
retention, and productivity. Glaukos offers a comprehensive orientation and onboarding program. All new
employees were invited to participate in our New Hire
46

Orientation. We continued to support managers in thehiring process, including a customizable onboarding
guide for new employees and managers and one-on-one
assistance with benefits enrollment. Central to Glaukos’
success is helping employees understand our industry as
well as our growing suite of medical device andpharmaceutical products. Within certain departments,
we offer formal on-the-job training. Our commercialorganization requires all sales representatives globally tocomplete and be certified on a multi-day basic training.
As part of their ongoing product knowledge, Sales
personnel receive regular, live product training, and go
through our Learning Management System, iLearn. Our
Clinical team has dedicated trainers to support consistency across those employees monitoring our studies.

INTERNSHIPS AT GLAUKOSAs part of our commitment toquality, all employees directly
involved in the manufacturing
process complete quality-specifictraining to ensure we maintain thehighest-quality product.

In 2023, we added six new leadership and interpersonal
skill development classes and resources: Negotiate to
Collaborate, Grow Your Development, Pre-Audit
Investigations, Source and Select, Glaukos World Café,and Glaukos Selling Skills. In 2024, our learning and development activities will expand with topics related toTrust, Change Leadership, and Oral Communications.

“The best part about interning at Glaukos was thestrong sense of community. Everyone always has
the desire to help, work together, and answer
questions. This manifests in amazing learning
opportunities. It’s great to have people lean on us,which prepares us really well for our future jobs. It
also makes work much more fun, productive, andgratifying.”— Quote from Summer 2023 intern
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION
A GREAT PLACE TO WORK...ANDSTAY

We continued our internship program in 2023. We hired
25 interns, our largest cohort to date. Over a 12-weekprogram, participants had access to peer and leadershipnetworking opportunities, career development training,and on-the-job learning. Notably, several internships wereextended to longer-term roles, highlighting the successand impact of the program.
At Glaukos, our performance management philosophy
focuses on current and forward-looking discussions that
we recommend take place quarterly to give employees
and managers a formal time to talk. We refer to this as our
Check-In Process. Our new “Grow Your Development”
class is linked to our Check-In focus areas: performance,
career, and development goal conversations. Over 60
employees attended this class in 2023.

Glaukos carefully analyzes when and where employees are needed and judiciously adds headcount. This is done to optimize company resources
and minimize the need for layoffs. Years of positive
Great Place to Work employee survey results andour own promotion and turnover statistics paint a
compelling picture that this is a great place towork and stay. Compared to peer companies in
the 2023 Aon Lifesciences and Medical Device
Industry Salary and Turnover Study, Glaukos
experienced:• Overall turnover of 7.5%, compared to overallturnover averages of 24.3%, 21.3%, and 23.3%
for Southern California, Northeast states andCentral/Midwest states, respectively.
• Promotion rate 50% above average (18.0% vs.

12.4% average promotion rate).
47

To further support our employees,
we also provide a Career and Performance Check-In job aid with tips andsuggestions about writing and updating goals and having meaningfulcareer discussions. Employees andmanagers work together to create
goals that help employees pursue
career development and promotion.

and templates to create and update their performance,development, and career goals. One module in Leader
Lab focuses on teaching people leaders how to better
facilitate Check-In conversations. Our leadership development class, Launch, explores why 1:1 meetings are criticalto employee growth and retention.
Employees and managers in the US have access toonline, dynamic tools through Oracle where goals can be
stored and updated; outside the US, employees and managers have a document to achieve the same thing. Where
appropriate, Glaukos does regular skills assessments to
identify potential skill gaps within specific departments. If
we identify a gap, we work with leaders to address it
through succession planning or targeted external recruitment efforts. The Succession and Talent Calibration process identified critical roles and successors, and the continually updated data was used to influence promotions
and development.
We continue to enhance and update Succession andTalent Calibration processes. In 2023, we completed
Succession and Talent Calibration discussions across thecompany and identified critical roles and successors
where possible. In late 2023, we converted our manual
Succession and Talent Calibration system to Oracle to be
implemented in Q1 2024.
Glaukos pushes the envelope on learning and captures
the traditional idea of a science fair with a new twist. In
December 2023, the Glaukos Board of Directors, andemployees from the 242-person Aliso Viejo campus
interacted with pipeline R&D products and the scientists
and engineers who led their development.

During Check-Ins, managers and employees discuss
performance and personal career and development
goals. All employees and their managers can access tools
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXTALENT ATTRACTION, DEVELOPMENT, ENGAGEMENT,AND RETENTION
Progress Toward Our Goals- Expanded trackless PTO to include all exempt em-

2023 Goals- Student Loan Repayment Program

Based on this year’s Great Place to Work engagement
survey results, identify areas of opportunity; communicate
and measure progress against improvement areas in thefollowing year

- Merge HSA, FSA, Wellness and Student Loan

Expand leadership and employee development for targeted employee groups with the addition of at least three newprograms; report employee hours of training globally andlearning outcomes for applicable programs by 2024

Glaukos used this year’s Great Places to Work engagement survey results to identify areas of opportunity andimplemented the following actions:•

Developed resources to help employees and people
leaders navigate promotion and development•

Implemented and piloted new learning and development activities•

Posted open positions internally•

Launched Glaukos World Café to promote explorationof Diversity, Equity, and Inclusion•

Designed and held Major Business Objective (MBO)
reviews for better cross-company planning andvisibility to company goals.

•

Designed and tested new SharePoint Intranet slatedfor Q1 2024 launch•

Revamped All Hands Meetings to include moreinteractive sessions and company knowledge sharing•

Designed company benefits slated for Q1 2024
implementation:48

ployees

Reimbursement Programs under Fidelity, making
it easier to access and manage reimbursements.
•

Continued Holiday Shutdown between December 25thand New Years Day•

Maintained hybrid work philosophy

Glaukos also implemented six new employee programs
and classes: Grow Your Development; Source and Select,
PAI Readiness, Negotiate to Collaborate, Glaukos Selling
Skills, Glaukos World Café. Verified employee training
hours increased by 60% from 2022, and learning
evaluations were designed and implemented for threeprograms.
For 2024, we plan to continue to identify opportunities for
improvement based upon the this year’s engagement
survey results and to strategically expand the leadershipand employee development activities with pilot launch ofat least three leadership and employee development
activities.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIX

DIVERSITY AND INCLUSION
Create and implement a lens of diversity, inclusion, and non-discrimination across the company and throughout the talent lifecycle.
GRI 3-3; GRI 405-1

At Glaukos, we believe that broader perspectives
increase our ability to drive innovation. We havesought to create a culture that positively impacts
our employees’ lives. We understand the power ofdiversity and the importance of an environment that
respects everyone’s identity. We aim for all employees tofeel valued for who they are and the unique perspectives
they bring.

Management Approach
Each Glaukos employee brings a different background,
set of skills, and perspective. Our diversity propels
creativity and innovation, resulting in increased value
for Glaukos.
The DEI Forum, created in 2021, comprises employees
representing a mix of genders, ethnicities, geographies,
and functional areas. The Forum met six times in 2023 andis sponsored by our CEO, Tom Burns, and chaired by our

Senior Vice-President, Human Resources, and our Chief
Development Officer.

The Forum is a community of colleagues who embrace
the rich perspectives and experiences that arise fromracial, ethnic, socio-economic, sexual, gender, physical,
and religious diversity. The Forum exists as an advisorygroup to:• Understand our current Diversity, Equity, and Inclusion

culture.
• Discuss and recommend new and better resources,

tools, and behaviors that nourish a rich Diversity, Equity,and Inclusion culture in which everyone is comfortableat work as their authentic selves.
• Act as visible Diversity, Equity, and Inclusionambassadors across Glaukos.
The Glaukos Human and Workforce Rights policy andAffirmative Action and Equal Opportunity (EEO)

Policy ensure every employee feels safe and welcome at
Glaukos. In the EEO Policy, we affirm that Glaukos is anequal opportunity employer and that we will take thefollowing steps to pursue a diverse and equitable
workforce: Glaukos recruits, hires, assigns, promotes, setscompensation, and takes all other employment actions
without regard to race, national origin, religion, age, color,
sex, sexual orientation, gender identity, disability,
protected veteran status, or any other characteristic
protected by local, state, or federal laws, rules, or regulations.
Glaukos uses the lens of DEI throughout the recruitment
process. We participate in targeted recruitment ofminority, women, veteran, and disabled job seekers by
funding online efforts. We also partner with a third-party
service, Circa, to pull job openings from our website anddisperse them through its Community and Diversity
Outreach Program to encourage diverse applicants in our

DIVERSITY STATISTICS
Board of Directors by Gender and Race/Ethnicity:

49

Senior Management by Gender:

Global Workforce by Gender:

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIX

DIVERSITY AND INCLUSION
hiring process. Additionally, when creating job ads, we use agender decoder to maintain gender neutrality and increase
accessibility for diverse groups. Through these efforts, we seek
to increase representation in the applicant pool for all workforce
levels, including senior management. These efforts help us
achieve our commitment to appropriate gender and minority
representation within the workforce.

U.S. WORKFORCE BY RACE/ETHNICITY

Research indicates that new hires, especially those who consider themselves a minority, are more likely to be slow to acclimate
or potentially leave a company if orientation and onboarding
are weak.1 To increase minority employee retention, we enhanced orientation and onboarding systems and processes,
utilizing the expertise of a cross-functional team of colleagues
responsible for the end-to-end onboarding process. Glaukos
believes effective onboarding and orientation are particularly
critical to DEI initiatives.

THE PINK GROUP
In 2020, at the height of COVID, Claudia Martins Silva, Market Development
Manager Brazil, identified a need to create relationships between and among
women leaders that also helped advance learning and business. Thus, Pink wasborn and its mission is to help female Glaukos and external ophthalmic
professionals explore the advancement of technologies in the fight against
chronic diseases such as glaucoma.

with information and how to best care for treating chronic glaucoma patients.
Although Claudia started the group, other Glaukos female employees facilitatedand interacted. Claudia noted, “We have always prioritized women in the “Pinkgroup”, so that the language and exchange of experiences reflected the way inwhich each clinic led by a woman behaves, from patient entry to loyalty andfollow-up.”

Claudia sought out each member individually and presented the possibility ofjoining forces in the Brazilian market, exchanging knowledge and successful
practices. The members of Pink have similar interests while having unique roles
and all members agree that it is challenging to balance intense work andpersonal lives. This blending of work and home life issues are explored in Pink
meetings. Members take time to share their priorities at home, how they workwith patients, and how they keep themselvs up-to-date on new technologies.
For example, Pink members explored best practices about adoption of the new
MIGS and how this impacted their routine in the office and in the OperatingRoom. They discussed how to better approach patients, how to be transparent
50

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIX

DIVERSITY AND INCLUSIONINAUGURAL DEI LEARNING SESSION

Our compensation approach promotes similar pay acrosssimilar roles in relevant markets. As a result, Glaukos isfocused on compensating employees based on their work,
regardless of race, ethnicity, or gender.
We are committed to equal pay for equal work. To advance our commitment to internal pay
equity and transparency, Glaukos conducts an annual pay equity analysis to evaluate the
distribution of merit, bonus, and RSUs. We regularly evaluate pay practices concerning newhires, promotions, and our annual affirmative action program. If we identify any gaps in pay
equity, that information is shared with business leaders and addressed accordingly. Starting
Jan. 1, 2023, California employers with 15 or more employees are required to include a
position's salary or hourly wage range (not including bonuses or equity-based compensation) in any internal or external job posting. For increased transparency, Glaukos discloses
wage ranges for all posted positions in the U.S.
To cultivate an inclusive environment for all employees in the U.S., we offer benefits that
support a range of employee living situations, personal needs, ages, genders, andorientations. Our comprehensive wellness, healthcare, and other benefit offerings
support DEI through:• Fertility and family planning• Parental leave policies• Healthcare for common-law partners and spouses• Subsidized backup childcare• Child and elder care resources• Flexible work options

Glaukos is committed to embedding diversity and inclusion into the culture of ourorganization and our employee development opportunities. Our Senior Director, Talentand Learning, is a Certified Diversity Professional (CDP), responsible for overseeing ourdevelopment programs. Our global Learning Management System, iLearn, has dozens of
DEI-specific courses in multiple languages available free of charge to all employees. The
learning toolkit also contains information on when and how to identify mentors. For
managers planning to interview and hire,
Embed DEI Into Onboarding for Inclusion That Lasts (no date) Training Industry. Available at: https://trainingindustry.com/articles/onboarding/embed-dei-into-onboarding-for-inclusion-that-lasts/ (Accessed: 01
March 2024).

51

Glaukos was pleased to offer its first formal DEI-related learning session,
Glaukos World Café Coffee n‘ Chat. Using feedback from hundreds of
employees globally about the content and design of DEI learning, Glaukos
World Café focuses on exploring and discussing DEI topics in a safe,
conversational atmosphere.
Glaukos World Café objectives:•

Learn and Grow Together: Regardless of where you are on your DEI
journey, there's always more to discover. Glaukos World Café isdesigned to meet you where you are and help you learn and grow.

•Propel Innovation: We firmly believe that diversity fuels creativity andinnovation. By embracing our differences, we unlock new perspectives
that drive business success.

•Inclusivity Matters: Glaukos is committed to creating an inclusive
environment where every voice is heard and valued. The Glaukos World
Café is a powerful vehicle for us to nurture this culture.

•

Access Resources: Gain access to a wealth of resources, tools, andinformation to deepen your understanding of DEI.

Over 80 people enrolled for the first module in a series called “Start with
Why: Approaching DEI with Authenticity.” We received positive feedbackon the session. One question asking,“How would you rate the training
experience overall?” received a 4.6
on a 5.0 scale (i.e., 94.6% found it
good or excellent) and 97.3% ofevaluations found the content
valuable to extremely valuable.
To invite participation and create
excitement, participants could ordera Glaukos World Café mug to bringto the virtual discussion!
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIX

DIVERSITY AND INCLUSIONWOMEN IN OPHTHALMOLOGY
Glaukos participates and supports Women in Ophthalmology (WIO) and believes in its mission to enhanceand improve the professional environment for women in ophthalmology. Like Glaukos, WIO encourages
diversity, impartiality, and economic parity, and strives to cultivate new opportunities for leadership,
education, and public service in the field of ophthalmology for current and future
generations.
Glaukos employees attended the 2023 Summer Symposium in Marco Island,
Florida. “This was a great event to meet women in ophthalmology from allover the country, who come together to support each other” said Jen Lindgren,
Regional Business Manager.

Glaukos offers a Source and Select class that includes asection on anti-bias in the hiring and selection process.
Furthermore, our leadership development program,
Leader Lab, also focuses on coaching leaders to be more
inclusive. This program teaches leaders facilitative
leadership skills and feedback tools to create a more
inclusive workplace.
The 2023 Great Place to Work survey results show ourcommitment to DEI. Glaukos demonstrated especiallystrong performance with a 95% positive rating for thestatement: “People are treated fairly regardless of their52• Why DEI. A formal communication led by our CEO and

Forum co-chairs to explore and describe what DEI
means and why it is important to Glaukos. We shared a“Why DEI” message at our February All Hands Meeting
to formally share and explain to employees ourapproach to DEI and why it is important to thecompany.
• DEI Communication. The Forum will work withcorporate communications and colleagues to share
progress and updates internally and externally about
Glaukos’ unique approach to DEI beginning in 2024.

Emily Kelly, Senior Regional Business Manager, said “The great thing about thisconference is that women are on stage and presenting 99% of the time. They
have a seat at the table, and a voice in the room, where so often they areoutnumbered. I believe that is how WIO originated - to give women an
opportunity to have a seat, and a voice.”
Symposium participants were excited about Glaukos’ products: “People were
thrilled to come by to talk about iStent infinite, and iLink. We had over 40
residents/fellows come through the iStent Inject and iStent infinite wet lab; joined
by Dr. Tosin Smith at our station” said Amy Murray, Commercial Area Director.

In 2022, the DEI Forum analyzed and identified three
primary focus areas to concentrate on that we continued
to implement in 2023:• DEI Learning and Training. The Forum identified andEmily, Jen, and Amy at the WIO
Summer Symposium

sexual orientation” and a 93% positive rating for the statement: “People are treated fairly regardless of their race.”
We aim to continue being a place where employees feel
welcomed and included.

Progress Toward our Goals
2023 Goals

As led by our DEI Forum, identify and implement at least twocompany-wide initiatives and success measures that will
expand Glaukos’ approach to diversity, equity, and inclusion

sponsored a variety of learning and development
resources and tools for employees to understand andapply important DEI-related concepts and behaviors atwork that included keynote and lunchtime presentationsat our Global Sales Meetings, the use of external DEI
consultants for team meetings, and the launch of
Glaukos World Café—a global DEI learning program for
all Glaukos employees. Glaukos also conducted four
“Women’s Listening Sessions.” A randomized list of
women at Glaukos globally was generated andparticipants were invited to attend a session. The
purpose was to share and discuss what the culture at
Glaukos is like for females and to use that insight toinform changes to programs and resources.
We will add more communications and learning activities
in 2024 to create positive change in our organization.
Moreover, we plan to develop strategic and intentional
recruitment outreach efforts to diverse candidates.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXWORKPLACE HEALTH AND SAFETY
Creating a company-wide culture of diversity, inclusion, and non-discrimination, including in the hiring process. Supporting healthy habits and building policies that promote
occupant health and well-being holistically to help enhance performance and attendance
GRI 3-3; GRI 403-2; GRI 403-3; GRI 403-5; GRI-403-6; GRI 403-7; GRI 403-9

The health and safety of our workforce is a toppriority for Glaukos. Through strong managementof workforce health and safety, we can continue to
avoid injury and illness, while fostering an environmentthat promotes physical safety and overall well-being topositively impact the lives of our employees.

Management Approach
We take great pride in creating a safe environment for our
employees and prioritizing proper oversight to ensure thehealth and safety of our workforce. We believe a safe
working environment will improve employee retention,
productivity, and satisfaction. Our Senior Manager ofEnvironmental Health & Safety (EH&S) is responsible foroverseeing daily responsibilities related to employee
health and safety. The EH&S Senior Manager reports
directly to the Senior Vice President of Operations. All
our facilities, which include administrative, laboratory, andmanufacturing space, are designed to ensure safety forour employees and visitors. Glaukos enacted andenforces the following policies intended to promote
safety for our employees:• Hazardous Waste Handling and Disposal• Laser Safety• Injury and Illness Prevention Program• Chemical Hygiene Program• Ergonomic Assessments

Our Injury and Illness Prevention Program is thefoundation of our overall workplace health and safety
programs. It is aligned to OSHA’s Title 8 of the California
Code of Regulations (CCR), section 3203. While theprogram is not required in Massachusetts, we do requireelements of it for our Corneal Health Burlington location.
The program defines key elements for the organization as53

it relates to health and safety. These elements include
management responsibilities, worker participation(communication), hazard identification and assessment,
hazard prevention and control, compliance, and training.
We established a cross-departmental Safety Committee tocommunicate safety information to their respective teams,
act as their department’s liaison to bring up safetyconcerns or questions, and work in collaboration with the
Glaukos EH&S Senior Manager to improve safety within
the organization. The Glaukos EH&S Senior Manager
conducts risk assessments and institutes controls intended
to eliminate hazards and minimize risks.

Glaukos is committed to minimizing
the risk of employee or contractor
fatalities, high-consequence workrelated injuries, and recordable
work-related injuries, evidenced byour low lost time incident rate.
In accordance with Glaukos’ Incident Investigation
Program, Glaukos investigates the cause and effect of
any injury that occurs in the workplace and takes
corrective action designed to avoid similar incidents
from happening in the future. Root cause analysis isperformed using the “5-Whys” process with the goal ofidentifying the corrective action most likely to prevent
reoccurrence.
Comprehensive training is imperative to keep our
workforce safe and prevent potential incidents. Every
Glaukos employee completes foundational safety training,and many employees receive additional safety trainingthat is specific to their role. The safety training includes
hazard communication, the use of personal protective
equipment, injury and illness prevention, emergency
response, and standard operating procedures. We traineach employee to identify unsafe conditions andencourage them to report safety concerns to theirsupervisor, Human Resources, or the Glaukos EH&S
Senior Manager immediately. We promote an open-door
policy, so our workforce feels comfortable reporting safetyconcerns. We will continue to review measures we cantake to maintain our workplace safety and ensure ahealthy environment for our employees.
As we continued to prioritize workplace safety andemployee well-being, we developed a new Environmental
Health and Safety (EH&S) training program for all our
Burlington employees at Glaukos, similar to that which isprovided to our employees in California. This comprehensive training initiative aims to provide a general overview
of environmental health and safety requirements andguidelines that are essential for our workforce. Just as weprioritize foundational safety training for all employees,
this new program will add an extra layer of knowledge,
encompassing various aspects of safety measures,
including hazard communication, proper use of personal
protective equipment, injury and illness prevention,
emergency response protocols, and adherence tostandard operating procedures.
We are dedicated to continuously reviewing andenhancing our safety measures, fostering a culture ofsafety, and maintaining a workplace that prioritizes thehealth and well-being of every employee. Throughinitiatives like this new EH&S training, we aim to reinforce
our commitment to providing a safe and healthy
environment for all employees at Glaukos.
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXWORKPLACE HEALTH AND SAFETY
In 2023, the EH&S Inspection program continued in San
Clemente and expanded to encompass our Aliso Viejo
and Burlington campuses. We continued focusing on high-risk areas, such as laboratories, clean rooms, manufacturing areas, and facility’s workshop areas. We successfully
maintained an average 85% completion rate each monthof the areas requiring inspection across all three sites. We
also conduct safety risk assessments in our highest-riskareas and assess processes and tasks to teach each group
how to identify and mitigate risk. Through these efforts,
we focus on taking a proactive approach to health andsafety.
To maintain a healthy work environment, Glaukos
implemented a Communicable Disease and Illness policy.

Since 2020, we require all employees upon beginning
employment to sign this policy acknowledging their
responsibilities as well as the Company’s commitment toprevent the potential spread of communicable diseases/
illness in the workplace and protect the wellness of ouremployees. Glaukos continues to focus on the health andsafety of its employees, both at work and in their daily
lives. In addition to providing its employees in ourheadquarter locations with onsite vaccination for COVID19 and the flu, Glaukos partnered with Kaiser to provide
participants biometric testing for blood pressure, totalcholesterol, glucose, and BMI calculations. Biometricscreenings help participants establish a baseline against
other potential health issues and provide a clear pictureof their overall health.

SAFETY CULTURE
At the heart of our organizational values lies a commitment to prioritizing injury and illness prevention,
fostering a culture where safety is integral to every aspect of our operations. Through a multifaceted approach that encompasses training programs, thorough EHS inspections, and engaging wellness initiatives,
we have cultivated an environment where safety is embraced as a collective responsibility. This shared
dedication is evidenced by our commendable total recordable incident rate of 0.28, demonstrating theefficacy of our proactive measures in mitigating risks and ensuring the welfare of our workforce.
Furthermore, the significant achievement of maintaining
two injury-free manufacturing facilities throughout 2023
highlights the effectiveness of our safety protocols. The
absence of lost-time injuries since 2020 further validates
our ongoing commitment to promoting employee healthand safety. As we continue to uphold safety as a corevalue, we remain steadfast in our pursuit of maintaining thehighest standards of occupational health and safety, fostering a workplace culture where safety is prioritized and employees are empowered to contribute to a safer working
environment.
54

Progress Toward our Goals
2023 Goals

Conduct an annual Health and Safety risk assessment andimplement at least one new initiative annually to mitigate the
top risk identified

In 2022, our company established a strategic objective
aimed at implementing an annual initiative to mitigate theprimary risk highlighted in our yearly health and safety risk
assessment. As part of our ongoing commitment toprioritize workplace safety and reduce the likelihood ofwork-related injuries among employees and contractors,
this year's focus of our annual risk assessment centered on
the safe handling of potent compounds utilized by our
research and development team.
Each compound possesses unique characteristics,
presenting distinct potential risks to individuals handlingthe materials and those in close proximity. To addressthese concerns comprehensively, Glaukos will construct a
dedicated laboratory room specifically designed forhandling potent compounds. This dedicated space willfeature powder containment hoods engineered tosafeguard employees against airborne contamination
during material handling. Access will be restricted solely
to authorized personnel trained in working with thesematerials, and stringent personal protective equipment
requirements will be mandated within the space to further
mitigate potential risks to employees.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXENVIRONMENTAL
Environmental impact is a fundamental
consideration across all Glaukos operations.

GOALS SET IN 2023

55

YE 2023
STATUSGOALS SET IN 2024

Expand ISO 14001 Certification to Burlington site by 2024

Maintain ISO 14001 Certification for San Clemente and Burlington
sites

Create GHG inventory for Scope 1 and 2 GHG emissions databy 2023

Establish standard design guidelines for new facilities to evaluateenergy efficiency and other environmental considerations

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXENVIRONMENTAL

Decreasing direct and indirect energy usage, improving energy efficiency, sourcing renewable energy, and reducing greenhouse gas emissions generated throughout the value chain. Minimizing operational waste, increasing recycling and reuse rates, and responsible management of hazardous waste. Increasing water efficiency and reducing overall
impact on water sources
GRI 3-3; GRI 303-5; GRI 306-3; SASB HC-MS-410a.1

Environmental impact is a fundamental consideration across all Glaukos operations. From formal
initiatives and goals to promoting a culture ofenvironmental consciousness, Glaukos has progressed in
our aim to increase awareness of environmental impact
while simultaneously decreasing our relative impact.

Management Approach
Glaukos’ Environmental Health and Safety Policy outlines
our commitment to protect the environment and comply
with applicable regulations and our established internal
company management systems. We aim to reduce our
impact on natural resources and drive continuous improvement to enhance our environmental performance.
To mitigate our environmental impact, we strive for
efficiency throughout our operations, particularly inenergy usage in our California facilities, which accounts formost of our impact. We comply with California’s Title 24
Building Energy Efficiency Standards for new construction
and when making building modifications. Our Senior
Manager of EH&S oversees environmental complianceassociated with waste, emissions, and discharge ofchemicals. The Senior Manager of Environmental, Health,and Safety (EHS) delivers biannual reviews concerningenergy usage, hazardous waste management, andpertinent environmental challenges with the executive
team, including the CEO.
Glaukos conducts environmental risk assessments to
identify and mitigate risk proactively. We monitor risks toensure we are in the best position to avoid negative
impacts. Environmental risk assessments are part ofGlaukos’ commitment to continuous improvement. Healthand Safety (EHS) inspections have been implemented
across our three campuses. These systematic inspections,56

which must be completed monthly, serve as a proactive
measure to assess designated areas within each facility,
preemptively identifying and addressing potential safety
or environmental risks, thereby averting potential issues
before they escalate. Nevertheless, we continue tomonitor them and assess how our continued growth asan organization and business will impact or have alreadygone through impacts by environmental risks. We utilize
our Environmental Management System (EMS) to minimize the effect of our operations on the environment.

EV CHARGINGAt Glaukos, we believe in not
only supporting our employees' professional growth but
also aligning with their values,
particularly when it comes toenvironmental consciousness.
The installation of electricvehicle (EV) chargers at our
Corporate Headquarters
exemplifies this commitment.
Hearing from employees who
utilize our EV chargers daily, reinforces our belief that sustainability is a collective effort. By providing thisinfrastructure, we not only demonstrate our support for eco-friendly transportation but also actively contribute to lowering the carbon footprint of our workforce.
Our encouragement of EV usage not only aligns with individual preferences but also serves a larger purposeof reducing fossil fuel consumption and greenhouse gas emissions. As the number of EVs on the roadcontinues to rise, Glaukos remains dedicated to fostering a workplace environment where employees canfeel proud to make environmentally responsible choices every day.
Employee Kevin Massey said, “I am extremely grateful that Glaukos has installed EV chargers. I use themevery day to charge my vehicle. This shows that Glaukos supports my values and is committed to being
environmentally friendly. Glaukos is lowering the carbon footprint of its employees because we areencouraged to drive our EVs to work, hence contributing less fossil fuel and greenhouse gas emissions.
Glaukos supports the increasing number of EVs on the road.”
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXENVIRONMENTAL
Glaukos also manages and monitors environmental performance through ISO 14001 andhas successfully certified all our manufacturing facilities to the standard, signifying ourcommitment to environmental management system standards.

Climate Change Risks
At Glaukos, we aim to maximize our positive impact on patients with our innovative products while minimizing our environmental footprint. To achieve this, we have identified andcalculated our Scope 1 and Scope 2 GHG emissions. Understanding our environmental
footprint will help us identify opportunities for improvement. While we evaluate how we
can minimize our impact on the environment, we are also looking at how to mitigate
climate change impacts on our facilities.
Our California sites are susceptible to natural disasters such as brush fires andearthquakes. To help address these concerns, the organization utilizes a two-site
model for storing work-in-progress and finished goods inventory and has createdbusiness continuity plans, established redundant IT servers in geographically dispersed
data centers with a data recovery process, and provided employees with laptops forremote access. Our Burlington site is designed with the same data protection as all ourother servers.

Waste
Glaukos is dedicated to minimizing landfill waste by actively engaging in recycling
initiatives. At all our facilities, we ensure the recycling of cardboard and paper materials.
Additionally, to further this commitment, designated recycling receptacles have been
strategically placed in break rooms across our campuses, simplifying the recycling process
for our employees. These receptacles are specifically designed to collect aluminum andplastic containers, reinforcing our efforts to encourage and facilitate responsible waste
disposal practices.
We periodically train our employees in the proper way to collect, handle, and dispose ofhazardous waste to prevent contamination. In 2022, we implemented bulking ourcorrosive liquids waste stream onsite to minimize the frequency of waste disposal pickup
trips and containers used for collection and disposal. In 2023, Glaukos built on these
efforts by increasing the frequency between pickups, reducing the number of disposedcontainers, and reusing the collection containers to reduce the costs required to purchase

LIGHTING UPGRADES

Energy and GHG Emissions
We have a Building Management System (BMS) in place at our Aliso Viejo facility withseveral features to reduce our environmental impact. Our BMS allows us the ability toschedule and control heating and air conditioning in the building and limit the use ofnatural resources to when the building is occupied. The system takes away the use of local
thermostats which allows the BMS to adjust, so each area is working together to achieve a
comfortable temperature. This eliminates one area from being in cooling mode while
another adjacent area is heating.
The site also has Mechoshades and Cooper Lighting Systems. Mechoshades are window
shades that track sunrise and sunset times with the use of three sensors mounted on thebuilding roof. This system allows for optimum window shade control to reduce radiantheat into the office spaces. The Cooper Lighting Controls system allows for timescheduled and motion sensor control of building lighting. This eliminates using electricity
in spaces that are unoccupied.
Scope 1 and 2 assessments have been successfully conducted, encompassing our directemissions and indirect energy-related emissions. The calculation of greenhouse gas(GHG) emissions has been executed, providing a comprehensive overview of ourenvironmental footprint.
57

At our Aliso Viejo campus, 49 parking lot light
fixtures were upgraded from high-pressure
sodium lamps to LED with Photovoltaic sensors
to automate the lighting controls.
At our Burlington campus,10 exterior building
lights and five parking lot lights were replacedwith LED lights in early 2024. The LED lights will
use at least 75% less electricity than the metal
halide fixtures.

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXENVIRONMENTAL
new ones. In addition, our Burlington site is evaluating theuse of compostable shipping containers and biodegradable cold packs for shipping our pharmaceutical products.
Please visit the Responsible Procurement Practices sectionof this report for more information.

Our hazardous waste management program, covered
within our EMS, remains ongoing. Glaukos is dedicated tominimizing hazardous waste generation, and continual
efforts have been made to stabilize hazardous waste
generation across our operations.

Water
Our water consumption is minimal as it is not a significant
part of our manufacturing processes. We utilize water at
our facilities for washrooms and landscaping. With operations of our San Clemente pharmaceutical manufacturingsite not occurring until late 2023, the potential alterations
in water usage are not expected to be immediately apparent. Any discernible changes in our water consumption
patterns are not anticipated to become evident until
sometime in 2024, following the establishment andsettling of our operational activities.

certification by 2024. The groundwork for this certification
journey began with an introductory meeting outlining ourintentions in December 2022, followed by the planned
onset of active implementation in Q1 2023.
In early 2023, we successfully achieved our 2022 goal ofestablishing a comprehensive Greenhouse Gas (GHG)
inventory encompassing Scope 1 and 2 emissions data forour sites in San Clemente, Aliso Viejo, and Burlington,
alongside our international offices in Germany, England,
and Japan. This accomplishment serves as a fundamental
baseline for guiding our future initiatives. In 2024, theseemissions will be thoroughly evaluated to identify
potential areas for enhancement and improvement. Thisevaluation aims to uncover opportunities for optimizing
our environmental impact and furthering our commitment
to sustainability. In addition, we plan to establish
standard design guidelines for new facilities to evaluateenergy efficiency and other environmental considerations.

Progress Toward our Goals
2023 Goals

Expand ISO 14001 Certification to Burlington site by 2024
Create GHG inventory for Scope 1 and 2 GHG emissions
data by 2023

Glaukos successfully completed the certification process
for our Burlington site ahead of schedule. The certification, adhering to the ISO 14001 standard, was achieved inAugust 2023. Our proactive approach commenced in
2021 with the attainment of ISO 14001 certification at our
San Clemente site. Subsequently, our plan aimed to pursue certification for the Burlington site, initially targeting
58

Glaukos Corporation | 2023 Sustainability ReportAppendix

INTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXSUSTAINABILITY PROGRAM GOALSGOALS SET IN 20231

YE 2023
STATUSGOALS SET IN 20241

GOVERNANCE
Completion of anti-bribery/anti-corruption training by 100% of new
or renewing distributors
ETHICS ANDCOMPLIANCERESPONSIBLE
PROCUREMENT
PRACTICESCYBERSECURITY
AND DATAPRIVACY

Annual certification by 100% of employees regarding compliancewith Code of Business Conduct and Ethics

In 2023, reduce percentage of Glaucoma medical device producttransported via air by developing 2nd site distribution center

Completion of anti-bribery/anti-corruption training by 100% of new or renewing
distributors and applicable new hires
Annual certification by 100% of employees regarding compliance with Code ofBusiness Conduct and Ethics
Review and refresh Code of Business Conduct and Ethics in 2024
Update R&D design development documents to require evaluation of sustainability
in product design and packaging
By 2027, change from paper IFUs to electronic for all medical devices (wherepermitted by regulation)

In 2023, convert Corneal Health Photrexa cross-linking kits’
packaging and shipment materials to biodegradable materials,
reducing waste and implementing cost savings

Conduct engineering evaluation of conversion to biodegradable Corneal Healthpackaging in 2024

By 2025, formally track alignment of the information security
program to relevant components of the NIST security framework
based upon risk to Glaukos and industry best practices

By 2025, formally track alignment of the information security program to relevant
components of the NIST security framework based upon risk to Glaukos and industry
best practices

Zero product recalls

Zero product recalls

100% of employees complete Product Quality training

100% of employees complete Product Quality training

FDA submissions of pipeline technologies that would allow us tomeet our publicly stated targets for FDA approvals

FDA submissions of pipeline technologies that would allow us to meet our publicly
stated targets for FDA approvals

Advancement of key clinical programs

Advancement of key clinical programs

PRODUCTSPRODUCTQUALITY AND
PATIENT SAFETY

PRODUCTINNOVATIONACCESS,
AFFORDABILITY,
AND PRICING

In 2024, help >5,000 patients navigate their keratoconus treatment journey
Increase number of patients who receive assistance from one of
Glaukos’ assistance programs

Establish process to make iDose accessible to underserved communities via iDoseYour Dose program

1 Where no year is mentioned, the goal is an annual goal to be pursued ad infinitum. Bolded goals are new for 2024.

60

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXSUSTAINABILITY PROGRAM GOALSGOALS SET IN 20231

YE 2023
STATUSGOALS SET IN 20241

PRODUCTS (Continued)
In coordination with patient advocacy organizations, support patients witheducational materials to build awareness of early intervention, find community, andmanage their disease
ACCESS,
AFFORDABILITY,
AND PRICING

Increase number of patients who receive assistance from one of
Glaukos’ assistance programs

By 2025, provide a comprehensive range of services to U.S. patients and caregivers
enrolled through a healthcare provider of self-enrolled to support the critical phaseof early decision-making about their keratoconus or glaucoma care
By 2027, develop a team of Patient Ambassadors to educate U.S. patient andadvocacy organizations
By 2030, surpass 10,000 cumulative stent donations and 150 recipient organizations

SOCIALTALENTATTRACTION,
DEVELOPMENT,ENGAGEMENT,AND RETENTION

DIVERSITY AND
INCLUSION

WORKPLACEHEALTH AND
SAFETY

Based on this year’s Great Place to Work engagement survey
results, identify areas of opportunity; communicate and measureprogress against improvement areas in the following year

Based on this year’s Great Place to Work engagement survey results, identify areasof opportunity; communicate and measure progress against improvement areas in
the following year

Expand leadership and employee development for targeted
employee groups with the addition of at least three new programs;
report employee hours of training globally and learning outcomesfor applicable programs by 2024

Continue the strategic expansion of leadership and employee development activities with pilot launch of at least three leadership and employee development activities

As led by our DEI Forum, identify and implement at least twocompany-wide initiatives and success measures that will expand
Glaukos’ approach to diversity, equity and inclusion by 2024

As led by our DEI Forum, continue to expand Glaukos’ approach to diversity, equity,and inclusion

Conduct an annual Health and Safety risk assessment and implement at least one new initiative annually to mitigate the top risk

Conduct an annual Health and Safety risk assessment and implement at least one
new initiative annually to mitigate the top risk identified

Expand ISO 14001 Certification to Burlington site by 2024

Maintain ISO 14001 Certification for San Clemente and Burlington sites

Create greenhouse gas (GHG) inventory for Scope 1 and 2 GHG
emissions data by 2023

Establish standard design guidelines for new facilities to evaluate energy efficiency
and other environmental considerations

Develop strategic and intentional recruitment outreach efforts to diverse candidates

ENVIRONMENTAL

1 Where no year is mentioned, the goal is an annual goal to be pursued ad infinitum. Bolded goals are new for 2024.

61

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXMETRICS AT-A-GLANCE
These metrics represent a good faith estimate by the Company of Glaukos’ historical calendar year data using methodology and processes we currently believe are appropriate. Thesemethodology and processes are periodically reviewed and evaluated. The metrics include all Glaukos locations globally unless otherwise stated.
± Information not tracked for these years.

TOPIC

METRIC

2023

2022

2021

2020

2019

Percentage of new or renewing third-party
distributors who completed our anti-bribery/anti-corruption training.

100%

100%

100%

±

±

Percentage of employees who completed
annual certification of our Code of BusinessConduct and Ethics

100%

100%

100%

±

±

Percentage of employees who completed
annual cybersecurity training

100%

100%

100%

±

±

Number of product recalls or take-backs

0

0

0

0

0

Number of products listed on the FDA’s MedWatch Safety Alerts for Human Medical Products database

0

0

0

0

0

Number of fatalities related to products

0

0

0

0

0

GOVERNANCE

Ethics and Compliance

Cybersecurity and Data Privacy
PRODUCT

Product Quality and Patient
SafetyProduct Innovation

Access, Affordability, andPricing

Number of FDA enforcement actions taken in
response to violations of current Good Manu00000
facturing Practices (cGMP)
Percentage of significant product and service
categories for which health and safety impacts
100%
100%
100%
100%
100%
are assessed for improvement
For information regarding currently anticipated new product launches, please see our filings with the U.S. Securities and Exchange Commission, accessible
here.
Value of product donations (amount in USD of$10.5
products donated to benefit underserved$9.6 million$7.4 million$3.5 million±
millionpatients)
Cumulative number of countries with patients
benefitting from product donations

53

48

45

45

±

Cumulative number of partnerships with humanitarian organizations

134

120

110+

107

±

Number of Employees

913

782

727

640

642

United States

779

658

614

534

±

International

134

124

113

106

±

SOCIAL
Talent Attraction, Development,
Engagement, and Retention
62

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXMETRICS AT-A-GLANCE± Information not tracked for these years.

TOPIC

METRIC

2023

2022

2021

2020

2019

Number of salary employees

719

640

586

524

±

Number of hourly employees

194

142

141

116

±

Permanent Employees
United States

913
779

782
658

727
614

640
534

642
±

International
Female
Male

134
364
548

124
295
487

113
271
456

106
±
±

±
±
±

Undisclosed
Full-time Employees
United States

1
906
775

0
777
654

±
±
±

±
±
±

±
±
±

International
Female
Male

131
360
545

123
294
483

±
±
±

±
±
±

±
±
±

Undisclosed
Part-time Employees
United States

1
7
4

±
5
4

±
±
±

±
±
±

±
±
±

International
Female
Male

3
4
3

1
1
4

±
±
±

±
±
±

±
±
±

200
92%
8%
45%
55%

144
88%
12%
46%
54%

179
87%
13%
43%
57%

99
83%
17%
40%
60%

±
±
±
±
±

47%

52%

50%

46%

±

35%
50%
15%
161
94%
6%
51%
49%

23%
60%
17%
127
98%
2%
37%
63%

21%
59%
19%
90
99%
1%
38%
62%

8%
64%
28%
51
±
±
35%
65%

±
±
±
±
±
±
±
±

57%

38%

51%

±

±

5.3%

11%

12.95%

9.01%±

SOCIAL

Talent Attraction, Development,
Engagement, and Retention(Continued)

63

Total New Hires1
United States
International
FemaleMale
From underrepresented communities (in theU.S.)2
Under 3030-50
50+
Total Promotions3
United States
International
FemaleMale
From underrepresented communities (in theU.S.)4
Turnover5
Voluntary turnover rate (%)

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXMETRICS AT-A-GLANCE± Information not tracked for these years.

TOPIC

METRIC

2023

2022

2021

2020

2019

Involuntary turnover rate (%)

2.2%

0.7%

0.74%

7.46%

±

Under 30

8.9%

17.3%

16.5%

19.4%

±

30-50

7.0%

11.4%

14.0%

15.4%

±

50+

8.0%

10.2%

12.3%

19.2%

±

Male

8.7%

10.0%

10.6%

16.4%

±

Female

5.7%

14.4%

18.8%

18.1%

±

Eligible

17

14

31

8

±

Used

17

14

31

8

±

Returned during the year (%)

100%

100%

81%

100%

±

Continues to be employee at year end (%)

94%

93%

84%

100%

±

Male

47%

64%

42%

50%

±

Female

53%

36%

58%

50%

±

Percentage of employees who completed theannual employee survey6 (%)

83%

83%

82%

±6

±

Equal opportunity policy which can be foundhere (Y/N)

Yes

Yes

Yes

Yes

Yes

Female

38%

38%

38%

14%

14%

Male
Board makeup by age (%)
Under 30

62%

62%

62%

86%

86%

0%

0%

0%

0%

0%

30-50

12%

12%

12%

0%

14%

50+
Senior management by gender7 (%)
FemaleMaleWorkforce by gender (%)
FemaleMale
Women in the workforce
Number of women employees in the workforce

88%

88%

88%

100%

86%

33%
67%

36%
64%

36%
64%

36%
64%

30%
70%

40%
60%

38%
62%

37%
63%

37%
63%

35%
65%

363

295

271

241

227

SOCIAL
Turnover by Age

Turnover by Gender

Talent Attraction, Development,
Engagement, and Retention(Continued)

Parental Leave Statistics

Board makeup by gender (%)

Diversity and Inclusion

64

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXMETRICS AT-A-GLANCE± Information not tracked for these years.

TOPIC

METRIC

2023

2022

2021

2020

2019

Number of women in senior management

4

±

±

±

±

Number of women in executive management

10

±

±

±

±

Number of women employees in new hires

89

66

77

±

±

Average years employed by the company forfemale employees

3.7

3.6

3.2

3.3

2.9

White/Non-Hispanic

55%

57%

58%

61%

±

Asian

22%

23%

23%

21%

±

Hispanic/Latino

12%

11%

12%

14%

±

Black/African American

2%

2%

1%

1%

±

Native Hawaiian or other Pacific Islander

0%

1%

1%

0%

±

Two or more race

7%

6%

5%

3%

±

Total number of US ethnic minority employees

340

283

255

207

±

Under 30

14%

11%

11%

10%

±

30-50

54%

57%

57%

58%

±

50+

32%

32%

32%

32%

±

Number of employee fatalities

0

0

0

0

0

Number of contractor fatalities

0

0

0

0

0

Number of high-consequence work-related
injuries

0

0

0

0

0

Lost time incident rate (total incidents per
200,000 hours worked/ per 100 full timeequivalent employees

0

0

0

0.20

±

Recordable incident rate (total incidents per
200,000 hours worked/per 100 FTE)

0.28

0.14

0.17

0.23

0.70

Number of fatalities as a result of work-related
ill health

0

0

0

0

0

Number of cases of recordable work-related illhealth

0

0

0

0

0

SOCIALU.S. workforce by race/ethnicity8 (%)

Diversity and Inclusion(Continued)

Workforce by age9 (%)

Workforce Health and Safety

65

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXMETRICS AT-A-GLANCE± Information not tracked for these years.

TOPIC

METRIC

2023

2022

2021

2020

2019

Aliso Viejo electricity consumption (kwh)

2,559,748

2,478,140

N/A

N/A

N/A

Burlington electricity consumption (kwh)

670,983

473,909

134,175

105,395

16,672San Clemente electricity consumption (kwh)

5,635,017

2,729,853

1,601,393

1,478,235

1,470,692

Total electrical consumption (kwh)

8,865,748

5,681,90210

1,735,568

1,583,630

1,487,364

Electricity intensity (kWh/$100,000)

2,187

2,008

590

704

628

Renewable sources of energy 11 (%)

58%

59%

45%

45%

±

Scope 1 GHG emissions

575.4

569.4

N/A

N/A

N/A

Scope 2 GHG emissions14

2,159.4

1,360.2

N/A

N/A

N/A

GHG Emissions Intensity

0.86

0.68

N/A

N/A

N/A

Aliso Viejo water consumption (gal)

N/A

N/A

N/A

N/A

N/A

Burlington water consumption (gal)

N/A

N/A

N/A

N/A

N/A

San Clemente water consumption (gal)1,075,624

1,318,724

1,455,608

1,152,668

1,577,741

Total water consumption (gallons)

1,075,624

1,318,724

1,455,608

1,152,668

1,577,741

Safe disposal of wastewater (y/n)

Yes

Yes

Yes

Yes

Yes

Water consumption intensity (Gal/$100,000)

341

466

628

643

683

Aliso Viejo Hazardous Waste generated

4,654

4,354

N/A

N/A

N/A

Burlington Hazardous Waste generated

1,900

242

26

N/A

N/A

San Clemente Hazardous Waste generated

8,734

6,700

11,251

9,561

8,974

Total Hazardous waste generated (pounds)

15,288

11,296

11,277

9,561

8,974

Total hazardous waste diverted from disposal

0

0

0

0

0

Total Hazardous Waste directed to disposal

15,288

11,296

11,277

9,561

8,974

Hazardous waste (lbs.)

15,288

11,296

11,277

9,561

8,974

Yes

Yes

Yes

Yes

Yes

ENVIRONMENTAL

Electricity

Emissions12

Water

Waste

13

Safe disposal of electronic waste (y/n)
66

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXMETRICS AT-A-GLANCETOPICMETRIC

2023

2022

2021

2020

2019

Aliso Viejo gas usage (therms)

88,372

88,293

Burlington gas usage (therms)

10,0889,541

21,454

N/A

N/A

4,030

4,492

San Clemente gas usage (therms)

4,260

658

4,481

4,203

3,773

4,033

Total usage (therms)
Gas intensity (therms/$100,000)

102,720

102,315

9,325

8,207

4,691

32.64

36.16

3.16

3.65

1.98

ENVIRONMENTAL

Gas

1.

We restated our 2019 and 2020 numbers to more accurately reflect tracking the employee population from the Avedro acquisition; the 2021-2023 numbers use the same consistent methodology.

2.

Underrepresented communities are defined as including persons who self-identify as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, and Alaska Native.

3.

We have restated our 2022 and 2021 Total Promotion number to more accurately reflect the tracking of the promotion status; the 2023 numbers use the same consistent methodology.

4.

Underrepresented communities are defined as including persons who self-identify as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, and Alaska Native

5.

Turnover includes layoffs from Avedro.

6.

Data previously reported for 2020 related to participation in our performance check-in process.

7.

Senior management includes members of senior management that participate in senior leadership weekly meetings. Most, but not all, of these individuals report to Tom Burns, CEO and Chairman of the Board. Data for 20182020 has been restated for consistency.

8.

Data for these categories reflect US-only workforce information, self-reported by our employees. The numbers presented in the 2020 Sustainability report also represented US -only data, rather than global workforce data.

9.

We have restated our 2020 numbers to more accurately reflect tracking the employee population from the Avedro acquisition; the 2021-2023 numbers use the same consistent methodology.

10. Our gas intensity increased significantly in 2022 due to the addition of our Aliso Viejo site as well as the return of remote employees back to the office on a hybrid schedule.
11. We are unable to track the exact percentage of our energy that derives from renewable sources. However, in 2023 and 2022, we have calculated an average percentage of the energy derived from renewable sources across all
three locations based upon public reports from our energy provider for San Clemente, San Diego Gas & Electric, Eversource, our electrical provider for Burlington, and our Aliso Viejo energy provider, Edison Electrical. For
2021 and 2020, the percentage of energy derived from renewal sources is based upon public information available from our energy provider for San Clemente, San Diego Gas & Electric.
12. Emissions include Aliso Viejo, San Clemente, and Burlington facilities. Invoices were not available for our Germany, UK, and Japan sites. Natural gas and electricity usage estimates were made based on climate zone, square
footage, and usage factors from the U.S. Energy Information Administration’s Commercial Buildings Energy Consumption Survey (CBESC).
13. Scope 1 emissions were calculated based on Glaukos’ natural gas usage, mobile vehicle emissions, and refrigerant usage.
a. Utility usage data was obtained from Glaukos’ invoices.
b. Fleet information, annual fuel consumption, and miles traveled were used to calculate mobile combustion emissions.
c. Refrigerant information and recharge quantities were provided for applicable facilities.
d. When invoices were not available, natural gas usage estimates are based on facility/office location, square footage, and usage factors from Commercial Buildings Consumption Survey (CBECS).
e. Combustion GHG emission factors were based on the USEPA's 40 Code of Federal Regulations (CFR) Part 98, and US EPA (2021) Inventory of U.S. Greenhouse Gas Emissions and Sinks.
Emission factors for the Scope 1 calculations are sourced based on the location of the facilities.
14. Scope 2 emissions were calculated based on Glaukos' electricity and steam usage.
a. Usage data was obtained from Glaukos’ invoices.
b. When invoices were not available, electricity usage estimates were typically based on building/office location, square footage, and usage factors from CBECS.
c. Electricity GHG emission factors were based on location-based emission factors using the USEPA's Emissions & Generation Resource Integrated Database (eGRID), UK Department for Environment, Food and Rural Affairs(DEFRA) 2022 Emission Factors for GHG Inventories and the International Energy Agency's emission factors for 2021. Per IEA's licensing requirements the emissions factors have been removed from this document.

67

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXGRI AND SASB CONTENT INDEX
Summarized below are the GRI and SASB disclosures included in the Glaukos 2023 Sustainability Report. The report is informed by GRI and SASB standards but is not currently intended
to align with them. The SASB Sustainability Accounting Standards that are referenced herein are drawn from the Biotechnology & Pharmaceuticals (HC-BP) and Medical Equipment &Supplies (HC-MS) industry standards.
Framework

Disclosure

Location/Response

General Disclosures 2023
The Organization and its Reporting Practices

GRI

2-1 Organizational details

Glaukos

2-2 Entities included in the organization’s sustainability reporting

Our Report

2-3 Reporting period, frequency and contact point

Our Report

2-4 Restatements of information

Any restatements of information have been footnoted within the report

Activities and Workers

GRI

2-6 Activities, value chain and other business relationships

Glaukos, Patient Focus and Novel Platforms; Responsible Procurement Practices; 2023 Form 10-K p. 79; No significant changes to Glaukos’ operations and its supply chain in 2023

2-7 Employees

Metrics at-a-Glance

2-9 Governance Structure and composition

Sustainability Governance and Sustainability Program Design; 2024 Proxy Statement p. 22-27

2-10 Nomination and selection of the highest governance body2024 Proxy Statement p. 29-30

2-11 Chair of the highest governance body2024 Proxy Statement p. 22

2-13 Delegation of responsibility for managing impacts

Sustainability Governance; Sustainability Program Design

2-14 Role of the highest governance body in sustainability reporting

Sustainability Program Design

2-15 Conflicts of interest

Ethics and Compliance; Code of Business Conduct and Ethics, p. 3-4

2-18 Evaluation of the performance of the highest governance bodyCompensation, Nominating and Governance Committee Charter; Audit Committee Charter

2-19 Remuneration policies

2024 Proxy Statement p. 17-19, 63-71

2-20 Process to determine remuneration

2024 Proxy Statement p. 48-61; Compensation, Nominating and Governance Committee Charter2-21 Annual total compensation ratio

2024 Proxy Statement p. 73

Governance

GRI

Strategy, Policies and Practices

GRI

68

2-22 Statement on sustainable development strategy

CEO Message

2-23 Policy commitments

Ethics and Compliance2-25 Processes to remediate negative impacts

Responsible Procurement Practices; Ethics and Compliance2-26 Mechanisms for seeking advice and raising concerns

Ethics and Compliance
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXGRI AND SASB CONTENT INDEX
Summarized below are the GRI and SASB disclosures included in the Glaukos 2023 Sustainability Report. The report is informed by GRI and SASB standards but is not currently intended
to align with them. The SASB Sustainability Accounting Standards that are referenced herein are drawn from the Biotechnology & Pharmaceuticals (HC-BP) and Medical Equipment &Supplies (HC-MS) industry standards.
Framework

Disclosure

Location/Response

General Disclosures 2023
Stakeholder Engagement

GRI

2-29 Approach to stakeholder engagement

Our stakeholders include customers, employee and non-employee workers, suppliers, shareholders
and other providers of capital, local communities and civil society
Sustainability Program Design2-30 Collective bargaining agreements

Metrics at-a-Glance

3-1 Process to determine material topics

Sustainability Program Design

3-2 List of material topics

Sustainability Program Design

Material Topics
GRI
Topic Disclosures

Ethics and Compliance
GRI

SASB

3-3 Management of Ethics and Compliance

Ethics and Compliance

HC-MS-270a.2

Ethics and Compliance, Marketing Practices

HC-BP-270a.2

Ethics and Compliance, Marketing Practices

HC-BP-510a.2

Ethics and Compliance

HC-MS-510a.2

Ethics and Compliance

HC-BP-260a.2

Ethics and Compliance

Responsible Procurement Practices

GRI

SASB

69

3-3 Management of Responsible Procurement Practices

Responsible Procurement Practices

308-1 New suppliers that were screened using environmental criteria

Responsible Procurement Practices

414-1 New suppliers that were screened using social criteria

Responsible Procurement Practices

HC-BP-430a.1

Responsible Procurement Practices

HC-MS-430a.1

Responsible Procurement Practices

HC-MS-430a.2

Responsible Procurement Practices

HC-MS-430a.3

Responsible Procurement Practices
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXGRI AND SASB CONTENT INDEX
Summarized below are the GRI and SASB disclosures included in the Glaukos 2023 Sustainability Report. The report is informed by GRI and SASB standards but is not currently intended
to align with them. The SASB Sustainability Accounting Standards that are referenced herein are drawn from the Biotechnology & Pharmaceuticals (HC-BP) and Medical Equipment &Supplies (HC-MS) industry standards.
Framework

Disclosure

Location/Response

Topic Disclosures
Cybersecurity and Data Privacy
GRI

3-3 Management of Cybersecurity and Data Privacy

Cybersecurity and Data Privacy

Product Quality and Patient Safety

GRI

SASB

3-3 Management of Product Quality and Patient Safety

Product Quality and Patient Safety

416-1 Assessment of the health and safety impacts of product andservice categories

Product Quality and Patient Safety; Metrics at-a-Glance416-2 Incidents of non-compliance concerning the health and safety
impacts of products and services

Product Quality and Patient Safety, Post-Approval Quality Management

HC-BP-250a.1

Metrics at-a-Glance

HC-BP-250a.2

Metrics at-a-Glance

HC-BP-250a.3

Metrics at-a-Glance

HC-BP-250a.4

Metrics at-a-Glance

HC-BP-250a.5

Metrics at-a-Glance

HC-MS-250a.1

Metrics at-a-Glance

HC-MS-250a.2

Metrics at-a-Glance

HC-MS-250a.3

Metrics at-a-Glance

HC-MS-250a.4

Metrics at-a-Glance

HC-MS-410a.2

Metrics at-a-Glance

Product Innovation
GRI

3-3 Management of Product Innovation

Product Innovation

SASB

HC-BP-000.B

Product Innovation; Glaukos currently has more than 14 products in R&D. The exact number of drugs
in R&D is confidential.

70

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXGRI AND SASB CONTENT INDEX
Summarized below are the GRI and SASB disclosures included in the Glaukos 2023 Sustainability Report. The report is informed by GRI and SASB standards but is not currently intended
to align with them. The SASB Sustainability Accounting Standards that are referenced herein are drawn from the Biotechnology & Pharmaceuticals (HC-BP) and Medical Equipment &Supplies (HC-MS) industry standards.
Framework

Disclosure

Location/Response

Topic Disclosures
Access, Affordability, and Pricing
GRI

3-3 Management of Access, Affordability, Pricing

Access, Affordability, and Pricing

SASB

HC-BP-240b.2

Access, Affordability, and Pricing

Talent Attraction, Development, and Retention

GRI

SASB

3-3 Management of Access, Affordability, Pricing

Access, Affordability, and Pricing

401-3 Parental leave

Metrics at-a-Glance403-6 Promotion of worker health

Talent, Attraction, Development, and Retention, Employee Wellness, Benefits, and Compensation

404-2 Programs for upgrading employee skills and transition assistanceprograms

Talent, Attraction, Development, and Retention, Employee Growth, Development, and Retention

404-3 Percentage of employees receiving regular performance andcareer development reviews

Talent, Attraction, Development, and Retention, Employee Growth, Development, and Retention

HC-BP-240b.2

Access, Affordability, and Pricing

Diversity and Inclusion
GRI

3-3 Management of Diversity and Inclusion

Diversity and Inclusion

405-1 Diversity of governance bodies and employees

Metrics at-a-Glance

Workforce Health and Safety

GRI

71

3-3 Management of Workforce Health and Safety

Workforce Health and Safety403-2 Hazard identification, risk assessment, and incident investigation

Workforce Health and Safety403-3 Occupational health services

Workforce Health and Safety403-5 Worker training on occupational health and safety

Workforce Health and Safety403-6 Promotion of worker health

Workforce Health and Safety403-7 Prevention and mitigation of occupational health and safety
impacts directly linked by business relationships

Workforce Health and Safety

403-9 Work-related injuries

Workforce Health and Safety; Metrics at-a-Glance
Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXGRI AND SASB CONTENT INDEX
Summarized below are the GRI and SASB disclosures included in the Glaukos 2023 Sustainability Report. The report is informed by GRI and SASB standards but is not currently intended
to align with them. The SASB Sustainability Accounting Standards that are referenced herein are drawn from the Biotechnology & Pharmaceuticals (HC-BP) and Medical Equipment &Supplies (HC-MS) industry standards.
Framework

Disclosure

Location/Response

3-3 Management of Environmental

Environmental

303-5 Water consumption

Environmental, Water

306-3 Waste generated

Environmental, Waste

306-4 Waste diverted from disposal

Environmental, Waste

306-5 Waste directed to disposal

Environmental, Waste

HC-MS-410a.1

Environmental

Topic Disclosures
Environmental

GRI

SASB

72

Glaukos Corporation | 2023 Sustainability ReportINTRODUCTIONABOUT USSUSTAINABILITY PROGRAM

GOVERNANCE

PRODUCTSSOCIALENVIRONMENTAL

APPENDIXDISCLAIMER
All statements other than statements of historical facts included in this report that address
activities, events, or developments that we expect, believe, or anticipate will or may occur
in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they arebased on current business aspirations and expectations about future events affecting us
and are subject to risks, uncertainties and factors relating to our operations and businessenvironment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied
by forward-looking statements in this report. The potential risks and uncertainties include,
without limitation, our ability to achieve the sustainability targets identified in the sustainability report.

We do not undertake any obligation to update, amend or clarify the statements set forth
herein, whether as a result of new information, future events or otherwise, except as may
be required under applicable securities law. In addition, historical, current and forwardlooking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, andassumptions that are subject to change in the future. The information included in, and any
issues identified as material for purposes of, this document may not be considered material for SEC reporting purposes. In the context of this disclosure, the term “material” is distinct from, and should not be confused with, such term as defined for SEC reporting purposes.

These risks, uncertainties, and factors related to Glaukos, and our business are describedin detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on February 23, 2024 . Our filings with the Securities and Exchange
Commission are available in the Investor Section of our website at www.glaukos.com or atwww.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. Readers are cautioned not to place undue reliance on any estimate, aspirational targets or forward-looking statement contained herein,
which speak only as of the date made.

73

Glaukos Corporation | 2023 Sustainability Report